var bibbase_data = {"data":"\"Loading..\"\n\n
\n\n \n\n \n\n \n \n\n \n\n \n \n\n \n\n \n
\n generated by\n \n \"bibbase.org\"\n\n \n
\n \n\n
\n\n \n\n\n
\n\n Excellent! Next you can\n create a new website with this list, or\n embed it in an existing web page by copying & pasting\n any of the following snippets.\n\n
\n JavaScript\n (easiest)\n
\n \n <script src=\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fusers%2F6607533%2Fcollections%2FZ7QT8Q9P%2Fitems%3Fkey%3DhGXLq241MCQA3ow7rlTIV2gY%26format%3Dbibtex%26limit%3D100&jsonp=1&jsonp=1\"></script>\n \n
\n\n PHP\n
\n \n <?php\n $contents = file_get_contents(\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fusers%2F6607533%2Fcollections%2FZ7QT8Q9P%2Fitems%3Fkey%3DhGXLq241MCQA3ow7rlTIV2gY%26format%3Dbibtex%26limit%3D100&jsonp=1\");\n print_r($contents);\n ?>\n \n
\n\n iFrame\n (not recommended)\n
\n \n <iframe src=\"https://bibbase.org/show?bib=https%3A%2F%2Fapi.zotero.org%2Fusers%2F6607533%2Fcollections%2FZ7QT8Q9P%2Fitems%3Fkey%3DhGXLq241MCQA3ow7rlTIV2gY%26format%3Dbibtex%26limit%3D100&jsonp=1\"></iframe>\n \n
\n\n

\n For more details see the documention.\n

\n
\n
\n\n
\n\n This is a preview! To use this list on your own web site\n or create a new web site from it,\n create a free account. The file will be added\n and you will be able to edit it in the File Manager.\n We will show you instructions once you've created your account.\n
\n\n
\n\n

To the site owner:

\n\n

Action required! Mendeley is changing its\n API. In order to keep using Mendeley with BibBase past April\n 14th, you need to:\n

    \n
  1. renew the authorization for BibBase on Mendeley, and
    2. \n
  2. update the BibBase URL\n in your page the same way you did when you initially set up\n this page.\n
    3. \n
\n

\n\n

\n \n \n Fix it now\n

\n
\n\n
\n\n\n
\n \n \n
\n
\n  \n 2021\n \n \n (10)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with COVID-19: REMAP-CAP randomized controlled trial.\n \n \n \n \n\n\n \n Arabi, Y. M.; Gordon, A. C.; and Investigators\", \". R.\n\n\n \n\n\n\n Intensive Care Medicine, 47(8): 867–886. August 2021.\n \n\n\n\n
\n\n\n\n \n \n \"Lopinavir-ritonavirPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{arabi_lopinavir-ritonavir_2021,\n\ttitle = {Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with {COVID}-19: {REMAP}-{CAP} randomized controlled trial},\n\tvolume = {47},\n\tissn = {0342-4642, 1432-1238},\n\tshorttitle = {Lopinavir-ritonavir and hydroxychloroquine for critically ill patients with {COVID}-19},\n\turl = {https://link.springer.com/10.1007/s00134-021-06448-5},\n\tdoi = {10.1007/s00134-021-06448-5},\n\tlanguage = {en},\n\tnumber = {8},\n\turldate = {2021-10-02},\n\tjournal = {Intensive Care Medicine},\n\tauthor = {Arabi, Yaseen M. and Gordon, Anthony C. and "the REMAP-CAP Investigators"},\n\tmonth = aug,\n\tyear = {2021},\n\tpages = {867--886},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Optimising a targeted test reduction intervention for patients admitted to the intensive care unit: The Targeted Intensive Care Test Ordering Cluster Trial intervention.\n \n \n \n \n\n\n \n Litton, E.; Atkinson, H.; Anstey, J.; Anstey, M.; Campbell, L. T.; Forbes, A.; Hahn, R.; Hooper, K.; Kasza, J.; Knapp, S.; McGain, F.; Ngyuen, N.; Pilcher, D.; Reddi, B.; Reid, C.; Robinson, S.; Thompson, K.; Webb, S.; and Young, P.\n\n\n \n\n\n\n Australian Critical Care,S1036731420303441. January 2021.\n \n\n\n\n
\n\n\n\n \n \n \"OptimisingPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{litton_optimising_2021,\n\ttitle = {Optimising a targeted test reduction intervention for patients admitted to the intensive care unit: {The} {Targeted} {Intensive} {Care} {Test} {Ordering} {Cluster} {Trial} intervention},\n\tissn = {10367314},\n\tshorttitle = {Optimising a targeted test reduction intervention for patients admitted to the intensive care unit},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S1036731420303441},\n\tdoi = {10.1016/j.aucc.2020.11.003},\n\tlanguage = {en},\n\turldate = {2021-06-10},\n\tjournal = {Australian Critical Care},\n\tauthor = {Litton, Edward and Atkinson, Helen and Anstey, James and Anstey, Matthew and Campbell, Lewis T. and Forbes, Andrew and Hahn, Rebecca and Hooper, Katherine and Kasza, Jessica and Knapp, Sharon and McGain, Forbes and Ngyuen, Nhi and Pilcher, David and Reddi, Benjamin and Reid, Chris and Robinson, Suzanne and Thompson, Kelly and Webb, Steve and Young, Paul},\n\tmonth = jan,\n\tyear = {2021},\n\tpages = {S1036731420303441},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n The Cuff Leak Test In Critically Ill Patients: An International Survey of Intensivists.\n \n \n \n \n\n\n \n Lewis, K.; Almubarak, Y.; Møller, M. H.; Jaeschke, R.; Perri, D.; Zhang, Y.; Du, B.; Nishida, O.; Ntoumenopoulos, G.; Saxena, M.; Truwit, J.; Young, P. J; Alshamsi, F.; Arabi, Y. M; Rochwerg, B.; Karachi, T.; Szczeklik, W.; Alshahrani, M.; Machado, F. R; Annane, D.; Antonelli, M.; Girard, T. D; Cook, D.; Baw, B.; Nanchal, R.; Piraino, T.; Guyatt, G.; Alhazzani, W.; The GUIDE Group; Thebane, L.; Soth, M.; Mbuagbaw, L.; Belley‐Cote, E.; Dionne, J.; Centofanti, J.; Oczkowski, S.; Sharma, S.; Junek, M.; and Alquraini, M.\n\n\n \n\n\n\n Acta Anaesthesiologica Scandinavica,aas.13838. May 2021.\n \n\n\n\n
\n\n\n\n \n \n \"ThePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{lewis_cuff_2021,\n\ttitle = {The {Cuff} {Leak} {Test} {In} {Critically} {Ill} {Patients}: {An} {International} {Survey} of {Intensivists}},\n\tissn = {0001-5172, 1399-6576},\n\tshorttitle = {The {Cuff} {Leak} {Test} {In} {Critically} {Ill} {Patients}},\n\turl = {https://onlinelibrary.wiley.com/doi/10.1111/aas.13838},\n\tdoi = {10.1111/aas.13838},\n\tlanguage = {en},\n\turldate = {2021-06-10},\n\tjournal = {Acta Anaesthesiologica Scandinavica},\n\tauthor = {Lewis, Kimberley and Almubarak, Yousef and Møller, Morten Hylander and Jaeschke, Roman and Perri, Dan and Zhang, Ying and Du, Bin and Nishida, Osamu and Ntoumenopoulos, George and Saxena, Manoj and Truwit, Jonathon and Young, Paul J and Alshamsi, Fayez and Arabi, Yaseen M and Rochwerg, Bram and Karachi, Tim and Szczeklik, Wojciech and Alshahrani, Muhammed and Machado, Flavia R and Annane, Djillali and Antonelli, Massimo and Girard, Timothy D and Cook, Deborah and Baw, Bandar and Nanchal, Rahul and Piraino, Thomas and Guyatt, Gordon and Alhazzani, Waleed and {The GUIDE Group} and Thebane, Lehana and Soth, Mark and Mbuagbaw, Lawrence and Belley‐Cote, Emille and Dionne, Joanna and Centofanti, John and Oczkowski, Simon and Sharma, Sunjay and Junek, Mats and Alquraini, Mustafa},\n\tmonth = may,\n\tyear = {2021},\n\tpages = {aas.13838},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n A survey of self-reported use of cricoid pressure amongst Australian and New Zealand anaesthetists: Attitudes and practice.\n \n \n \n \n\n\n \n Mistry, R.; Frei, D. R; Badenhorst, C.; and Broadbent, J.\n\n\n \n\n\n\n Anaesthesia and Intensive Care, 49(1): 62–69. January 2021.\n \n\n\n\n
\n\n\n\n \n \n \"APaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{mistry_survey_2021,\n\ttitle = {A survey of self-reported use of cricoid pressure amongst {Australian} and {New} {Zealand} anaesthetists: {Attitudes} and practice},\n\tvolume = {49},\n\tissn = {0310-057X, 1448-0271},\n\tshorttitle = {A survey of self-reported use of cricoid pressure amongst {Australian} and {New} {Zealand} anaesthetists},\n\turl = {http://journals.sagepub.com/doi/10.1177/0310057X20968841},\n\tdoi = {10.1177/0310057X20968841},\n\tabstract = {We conducted a survey of Australian and New Zealand anaesthetists designed to quantify self-reported use of cricoid pressure (CP) in patients presumed to be at risk of gastric regurgitation, and to ascertain the underlying justifications used to support individual practice. We aimed to identify the perceived benefits and harms associated with the use of CP and to explore the potential impact of medicolegal concerns on clinical decision-making. We also sought to ascertain the views of Australian and New Zealand anaesthetists on whether recommendations relating to CP should be included in airway management guidelines. We designed an electronic survey comprised of 15 questions that was emailed to 981 randomly selected Fellows of the Australian and New Zealand College of Anaesthetists (ANZCA) by the ANZCA Clinical Trials Network on behalf of the investigators. We received responses from 348 invitees (response rate 35.5\\%). Of the 348 respondents, 267 (76.9\\%) indicated that they would routinely use CP for patients determined to be at increased risk of gastric regurgitation. When asked whether participants believed the use of CP reduces the risk of gastric regurgitation, 39.8\\% indicated yes, 23.8\\% believed no and 36.3\\% were unsure. Of the respondents who indicated that they routinely performed CP, 159/267 (60\\%) indicated that concerns over the potential medicolegal consequences of omitting CP in a patient who subsequently aspirates was one of the main reasons for using CP. The majority (224/337; 66\\%) of respondents believed that recommendations about the use of CP in airway management guidelines should include individual practitioner judgement, while only 55/337 (16\\%) respondents believed that routine CP should be advocated in contemporary emergency airway management guidelines.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2021-04-30},\n\tjournal = {Anaesthesia and Intensive Care},\n\tauthor = {Mistry, Ravi and Frei, Daniel R and Badenhorst, Chris and Broadbent, James},\n\tmonth = jan,\n\tyear = {2021},\n\tpages = {62--69},\n}\n\n
\n
\n\n\n
\n We conducted a survey of Australian and New Zealand anaesthetists designed to quantify self-reported use of cricoid pressure (CP) in patients presumed to be at risk of gastric regurgitation, and to ascertain the underlying justifications used to support individual practice. We aimed to identify the perceived benefits and harms associated with the use of CP and to explore the potential impact of medicolegal concerns on clinical decision-making. We also sought to ascertain the views of Australian and New Zealand anaesthetists on whether recommendations relating to CP should be included in airway management guidelines. We designed an electronic survey comprised of 15 questions that was emailed to 981 randomly selected Fellows of the Australian and New Zealand College of Anaesthetists (ANZCA) by the ANZCA Clinical Trials Network on behalf of the investigators. We received responses from 348 invitees (response rate 35.5%). Of the 348 respondents, 267 (76.9%) indicated that they would routinely use CP for patients determined to be at increased risk of gastric regurgitation. When asked whether participants believed the use of CP reduces the risk of gastric regurgitation, 39.8% indicated yes, 23.8% believed no and 36.3% were unsure. Of the respondents who indicated that they routinely performed CP, 159/267 (60%) indicated that concerns over the potential medicolegal consequences of omitting CP in a patient who subsequently aspirates was one of the main reasons for using CP. The majority (224/337; 66%) of respondents believed that recommendations about the use of CP in airway management guidelines should include individual practitioner judgement, while only 55/337 (16%) respondents believed that routine CP should be advocated in contemporary emergency airway management guidelines.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Mortality outcomes with hydroxychloroquine and chloroquine in COVID-19 from an international collaborative meta-analysis of randomized trials.\n \n \n \n \n\n\n \n Axfors, C.; Schmitt, A. M.; Janiaud, P.; van’t Hooft, J.; Abd-Elsalam, S.; Abdo, E. F.; Abella, B. S.; Akram, J.; Amaravadi, R. K.; Angus, D. C.; Arabi, Y. M.; Azhar, S.; Baden, L. R.; Baker, A. W.; Belkhir, L.; Benfield, T.; Berrevoets, M. A. H.; Chen, C.; Chen, T.; Cheng, S.; Cheng, C.; Chung, W.; Cohen, Y. Z.; Cowan, L. N.; Dalgard, O.; de Almeida e Val, F. F.; de Lacerda, M. V. G.; de Melo, G. C.; Derde, L.; Dubee, V.; Elfakir, A.; Gordon, A. C.; Hernandez-Cardenas, C. M.; Hills, T.; Hoepelman, A. I. M.; Huang, Y.; Igau, B.; Jin, R.; Jurado-Camacho, F.; Khan, K. S.; Kremsner, P. G.; Kreuels, B.; Kuo, C.; Le, T.; Lin, Y.; Lin, W.; Lin, T.; Lyngbakken, M. N.; McArthur, C.; McVerry, B. J.; Meza-Meneses, P.; Monteiro, W. M.; Morpeth, S. C.; Mourad, A.; Mulligan, M. J.; Murthy, S.; Naggie, S.; Narayanasamy, S.; Nichol, A.; Novack, L. A.; O’Brien, S. M.; Okeke, N. L.; Perez, L.; Perez-Padilla, R.; Perrin, L.; Remigio-Luna, A.; Rivera-Martinez, N. E.; Rockhold, F. W.; Rodriguez-Llamazares, S.; Rolfe, R.; Rosa, R.; Røsjø, H.; Sampaio, V. S.; Seto, T. B.; Shehzad, M.; Soliman, S.; Stout, J. E.; Thirion-Romero, I.; Troxel, A. B.; Tseng, T.; Turner, N. A.; Ulrich, R. J.; Walsh, S. R.; Webb, S. A.; Weehuizen, J. M.; Velinova, M.; Wong, H.; Wrenn, R.; Zampieri, F. G.; Zhong, W.; Moher, D.; Goodman, S. N.; Ioannidis, J. P. A.; and Hemkens, L. G.\n\n\n \n\n\n\n Nature Communications, 12(1): 2349. December 2021.\n \n\n\n\n
\n\n\n\n \n \n \"MortalityPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{axfors_mortality_2021,\n\ttitle = {Mortality outcomes with hydroxychloroquine and chloroquine in {COVID}-19 from an international collaborative meta-analysis of randomized trials},\n\tvolume = {12},\n\tissn = {2041-1723},\n\turl = {http://www.nature.com/articles/s41467-021-22446-z},\n\tdoi = {10.1038/s41467-021-22446-z},\n\tabstract = {Abstract\n            \n              Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or early discontinuation. We aim to estimate the effects of hydroxychloroquine and chloroquine on survival in COVID-19 from all currently available RCT evidence, published and unpublished. We present a rapid meta-analysis of ongoing, completed, or discontinued RCTs on hydroxychloroquine or chloroquine treatment for any COVID-19 patients (protocol:\n              https://osf.io/QESV4/\n              ). We systematically identified unpublished RCTs (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Cochrane COVID-registry up to June 11, 2020), and published RCTs (PubMed, medRxiv and bioRxiv up to October 16, 2020). All-cause mortality has been extracted (publications/preprints) or requested from investigators and combined in random-effects meta-analyses, calculating odds ratios (ORs) with 95\\% confidence intervals (CIs), separately for hydroxychloroquine and chloroquine. Prespecified subgroup analyses include patient setting, diagnostic confirmation, control type, and publication status. Sixty-three trials were potentially eligible. We included 14 unpublished trials (1308 patients) and 14 publications/preprints (9011 patients). Results for hydroxychloroquine are dominated by RECOVERY and WHO SOLIDARITY, two highly pragmatic trials, which employed relatively high doses and included 4716 and 1853 patients, respectively (67\\% of the total sample size). The combined OR on all-cause mortality for hydroxychloroquine is 1.11 (95\\% CI: 1.02, 1.20; I² = 0\\%; 26 trials; 10,012 patients) and for chloroquine 1.77 (95\\%CI: 0.15, 21.13, I² = 0\\%; 4 trials; 307 patients). We identified no subgroup effects. We found that treatment with hydroxychloroquine is associated with increased mortality in COVID-19 patients, and there is no benefit of chloroquine. Findings have unclear generalizability to outpatients, children, pregnant women, and people with comorbidities.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2021-04-28},\n\tjournal = {Nature Communications},\n\tauthor = {Axfors, Cathrine and Schmitt, Andreas M. and Janiaud, Perrine and van’t Hooft, Janneke and Abd-Elsalam, Sherief and Abdo, Ehab F. and Abella, Benjamin S. and Akram, Javed and Amaravadi, Ravi K. and Angus, Derek C. and Arabi, Yaseen M. and Azhar, Shehnoor and Baden, Lindsey R. and Baker, Arthur W. and Belkhir, Leila and Benfield, Thomas and Berrevoets, Marvin A. H. and Chen, Cheng-Pin and Chen, Tsung-Chia and Cheng, Shu-Hsing and Cheng, Chien-Yu and Chung, Wei-Sheng and Cohen, Yehuda Z. and Cowan, Lisa N. and Dalgard, Olav and de Almeida e Val, Fernando F. and de Lacerda, Marcus V. G. and de Melo, Gisely C. and Derde, Lennie and Dubee, Vincent and Elfakir, Anissa and Gordon, Anthony C. and Hernandez-Cardenas, Carmen M. and Hills, Thomas and Hoepelman, Andy I. M. and Huang, Yi-Wen and Igau, Bruno and Jin, Ronghua and Jurado-Camacho, Felipe and Khan, Khalid S. and Kremsner, Peter G. and Kreuels, Benno and Kuo, Cheng-Yu and Le, Thuy and Lin, Yi-Chun and Lin, Wu-Pu and Lin, Tse-Hung and Lyngbakken, Magnus Nakrem and McArthur, Colin and McVerry, Bryan J. and Meza-Meneses, Patricia and Monteiro, Wuelton M. and Morpeth, Susan C. and Mourad, Ahmad and Mulligan, Mark J. and Murthy, Srinivas and Naggie, Susanna and Narayanasamy, Shanti and Nichol, Alistair and Novack, Lewis A. and O’Brien, Sean M. and Okeke, Nwora Lance and Perez, Léna and Perez-Padilla, Rogelio and Perrin, Laurent and Remigio-Luna, Arantxa and Rivera-Martinez, Norma E. and Rockhold, Frank W. and Rodriguez-Llamazares, Sebastian and Rolfe, Robert and Rosa, Rossana and Røsjø, Helge and Sampaio, Vanderson S. and Seto, Todd B. and Shehzad, Muhammad and Soliman, Shaimaa and Stout, Jason E. and Thirion-Romero, Ireri and Troxel, Andrea B. and Tseng, Ting-Yu and Turner, Nicholas A. and Ulrich, Robert J. and Walsh, Stephen R. and Webb, Steve A. and Weehuizen, Jesper M. and Velinova, Maria and Wong, Hon-Lai and Wrenn, Rebekah and Zampieri, Fernando G. and Zhong, Wu and Moher, David and Goodman, Steven N. and Ioannidis, John P. A. and Hemkens, Lars G.},\n\tmonth = dec,\n\tyear = {2021},\n\tpages = {2349},\n}\n\n
\n
\n\n\n
\n Abstract Substantial COVID-19 research investment has been allocated to randomized clinical trials (RCTs) on hydroxychloroquine/chloroquine, which currently face recruitment challenges or early discontinuation. We aim to estimate the effects of hydroxychloroquine and chloroquine on survival in COVID-19 from all currently available RCT evidence, published and unpublished. We present a rapid meta-analysis of ongoing, completed, or discontinued RCTs on hydroxychloroquine or chloroquine treatment for any COVID-19 patients (protocol: https://osf.io/QESV4/ ). We systematically identified unpublished RCTs (ClinicalTrials.gov, WHO International Clinical Trials Registry Platform, Cochrane COVID-registry up to June 11, 2020), and published RCTs (PubMed, medRxiv and bioRxiv up to October 16, 2020). All-cause mortality has been extracted (publications/preprints) or requested from investigators and combined in random-effects meta-analyses, calculating odds ratios (ORs) with 95% confidence intervals (CIs), separately for hydroxychloroquine and chloroquine. Prespecified subgroup analyses include patient setting, diagnostic confirmation, control type, and publication status. Sixty-three trials were potentially eligible. We included 14 unpublished trials (1308 patients) and 14 publications/preprints (9011 patients). Results for hydroxychloroquine are dominated by RECOVERY and WHO SOLIDARITY, two highly pragmatic trials, which employed relatively high doses and included 4716 and 1853 patients, respectively (67% of the total sample size). The combined OR on all-cause mortality for hydroxychloroquine is 1.11 (95% CI: 1.02, 1.20; I² = 0%; 26 trials; 10,012 patients) and for chloroquine 1.77 (95%CI: 0.15, 21.13, I² = 0%; 4 trials; 307 patients). We identified no subgroup effects. We found that treatment with hydroxychloroquine is associated with increased mortality in COVID-19 patients, and there is no benefit of chloroquine. Findings have unclear generalizability to outpatients, children, pregnant women, and people with comorbidities.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n The Effect of Early Sedation With Dexmedetomidine on Body Temperature in Critically Ill Patients.\n \n \n \n \n\n\n \n Grayson, K. E.; Bailey, M.; Balachandran, M.; Banneheke, P. P.; Belletti, A.; Bellomo, R.; Naorungroj, T.; Serpa-Neto, A.; Wright, J. D.; Yanase, F.; Young, P. J.; and Shehabi, Y.\n\n\n \n\n\n\n Critical Care Medicine, Publish Ahead of Print. February 2021.\n \n\n\n\n
\n\n\n\n \n \n \"ThePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{grayson_effect_2021,\n\ttitle = {The {Effect} of {Early} {Sedation} {With} {Dexmedetomidine} on {Body} {Temperature} in {Critically} {Ill} {Patients}},\n\tvolume = {Publish Ahead of Print},\n\tissn = {0090-3493},\n\turl = {https://journals.lww.com/10.1097/CCM.0000000000004935},\n\tdoi = {10.1097/CCM.0000000000004935},\n\tlanguage = {en},\n\turldate = {2021-04-28},\n\tjournal = {Critical Care Medicine},\n\tauthor = {Grayson, Kim E. and Bailey, Michael and Balachandran, Mayurathan and Banneheke, Piyusha P. and Belletti, Alessandro and Bellomo, Rinaldo and Naorungroj, Thummaporn and Serpa-Neto, Ary and Wright, Jason D. and Yanase, Fumitaka and Young, Paul J. and Shehabi, Yahya},\n\tmonth = feb,\n\tyear = {2021},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Is less really more for oxygen therapy in patients with acute respiratory failure?.\n \n \n \n \n\n\n \n Young, P. J.; Gladwin, B.; and Capdevila, M.\n\n\n \n\n\n\n Anaesthesia Critical Care & Pain Medicine, 40(2): 100858. April 2021.\n \n\n\n\n
\n\n\n\n \n \n \"IsPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{young_is_2021,\n\ttitle = {Is less really more for oxygen therapy in patients with acute respiratory failure?},\n\tvolume = {40},\n\tissn = {23525568},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S2352556821000618},\n\tdoi = {10.1016/j.accpm.2021.100858},\n\tlanguage = {en},\n\tnumber = {2},\n\turldate = {2021-04-28},\n\tjournal = {Anaesthesia Critical Care \\& Pain Medicine},\n\tauthor = {Young, Paul J. and Gladwin, Benjamin and Capdevila, Mathieu},\n\tmonth = apr,\n\tyear = {2021},\n\tpages = {100858},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n New‐onset atrial fibrillation in the intensive care unit: Protocol for an international inception cohort study (AFIB‐ICU).\n \n \n \n \n\n\n \n Wetterslev, M.; Møller, M. H.; Granholm, A.; Haase, N.; Hassager, C.; Lange, T.; Hästbacka, J.; Wilkman, E.; Myatra, S. N.; Shen, J.; An, Y.; Siegemund, M.; Young, P. J; Aslam, T. N.; Szczeklik, W.; Aneman, A.; Arabi, Y. M.; Cronhjort, M.; Keus, F.; and Perner, A.\n\n\n \n\n\n\n Acta Anaesthesiologica Scandinavica,aas.13827. April 2021.\n \n\n\n\n
\n\n\n\n \n \n \"New‐onsetPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{wetterslev_newonset_2021,\n\ttitle = {New‐onset atrial fibrillation in the intensive care unit: {Protocol} for an international inception cohort study ({AFIB}‐{ICU})},\n\tissn = {0001-5172, 1399-6576},\n\tshorttitle = {New‐onset atrial fibrillation in the intensive care unit},\n\turl = {https://onlinelibrary.wiley.com/doi/10.1111/aas.13827},\n\tdoi = {10.1111/aas.13827},\n\tlanguage = {en},\n\turldate = {2021-04-28},\n\tjournal = {Acta Anaesthesiologica Scandinavica},\n\tauthor = {Wetterslev, Mik and Møller, Morten Hylander and Granholm, Anders and Haase, Nicolai and Hassager, Christian and Lange, Theis and Hästbacka, Johanna and Wilkman, Erika and Myatra, Sheila Nainan and Shen, Jiawei and An, Youzhong and Siegemund, Martin and Young, Paul J and Aslam, Tayyba N. and Szczeklik, Wojciech and Aneman, Anders and Arabi, Yaseen M. and Cronhjort, Maria and Keus, Frederik and Perner, Anders},\n\tmonth = apr,\n\tyear = {2021},\n\tpages = {aas.13827},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Effect of Oxygen Therapy on Mortality in the ICU.\n \n \n \n\n\n \n Young, P. J.\n\n\n \n\n\n\n The New England Journal of Medicine, 384(14): 1361–1363. April 2021.\n \n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{young_effect_2021,\n\ttitle = {Effect of {Oxygen} {Therapy} on {Mortality} in the {ICU}},\n\tvolume = {384},\n\tissn = {1533-4406},\n\tdoi = {10.1056/NEJMe2101538},\n\tlanguage = {eng},\n\tnumber = {14},\n\tjournal = {The New England Journal of Medicine},\n\tauthor = {Young, Paul J.},\n\tmonth = apr,\n\tyear = {2021},\n\tpmid = {33826824},\n\tkeywords = {Humans, Intensive Care Units, Oxygen, Oxygen Inhalation Therapy, Respiratory Insufficiency},\n\tpages = {1361--1363},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Interleukin-6 Receptor Antagonists in Critically Ill Patients with Covid-19.\n \n \n \n \n\n\n \n The REMAP-CAP Investigators\n\n\n \n\n\n\n New England Journal of Medicine,NEJMoa2100433. February 2021.\n \n\n\n\n
\n\n\n\n \n \n \"Interleukin-6Paper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{the_remap-cap_investigators_interleukin-6_2021,\n\ttitle = {Interleukin-6 {Receptor} {Antagonists} in {Critically} {Ill} {Patients} with {Covid}-19},\n\tissn = {0028-4793, 1533-4406},\n\turl = {http://www.nejm.org/doi/10.1056/NEJMoa2100433},\n\tdoi = {10.1056/NEJMoa2100433},\n\tlanguage = {en},\n\turldate = {2021-02-28},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {{The REMAP-CAP Investigators}},\n\tmonth = feb,\n\tyear = {2021},\n\tpages = {NEJMoa2100433},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2020\n \n \n (14)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Could stress ulcer prophylaxis increase mortality in high-acuity patients?.\n \n \n \n \n\n\n \n Harhay, M. O.; Young, P. J.; and Shankar-Hari, M.\n\n\n \n\n\n\n Intensive Care Medicine, 46(4): 793–795. April 2020.\n \n\n\n\n
\n\n\n\n \n \n \"CouldPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{harhay_could_2020,\n\ttitle = {Could stress ulcer prophylaxis increase mortality in high-acuity patients?},\n\tvolume = {46},\n\tissn = {0342-4642, 1432-1238},\n\turl = {http://link.springer.com/10.1007/s00134-020-05959-x},\n\tdoi = {10.1007/s00134-020-05959-x},\n\tlanguage = {en},\n\tnumber = {4},\n\turldate = {2021-05-20},\n\tjournal = {Intensive Care Medicine},\n\tauthor = {Harhay, Michael O. and Young, Paul J. and Shankar-Hari, Manu},\n\tmonth = apr,\n\tyear = {2020},\n\tpages = {793--795},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Outcomes of patients with subarachnoid haemorrhage admitted to Australian and New Zealand intensive care units following a cardiac arrest.\n \n \n \n\n\n \n Heaney, J.; Paul, E.; Pilcher, D.; Lin, C.; Udy, A.; and Young, P. J.\n\n\n \n\n\n\n Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 22(3): 237–244. September 2020.\n \n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{heaney_outcomes_2020,\n\ttitle = {Outcomes of patients with subarachnoid haemorrhage admitted to {Australian} and {New} {Zealand} intensive care units following a cardiac arrest},\n\tvolume = {22},\n\tissn = {1441-2772},\n\tabstract = {OBJECTIVES: To describe the characteristics and outcomes of adults with a subarachnoid haemorrhage (SAH) admitted to Australian and New Zealand intensive care units (ICUs) with a cardiac arrest in the preceding 24 hours.\nDESIGN: Retrospective cohort study.\nSETTING: Study data from 144 Australian and New Zealand ICUs were obtained from the Australian and New Zealand Intensive Care Society Centre for Outcome and Resource Evaluation Adult Patient Database.\nPARTICIPANTS: A total of 439 of 11 047 (3.9\\%) patients admitted to an ICU with a SAH had a documented cardiac arrest in the 24 hours preceding their ICU admission. The mean age of patients with SAH and a preceding cardiac arrest was 55.3 years (SD, 13.7) and 251 of 439 (57.2\\%) were female.\nMAIN OUTCOME MEASURES: The primary outcome of interest was in-hospital mortality. Key secondary outcomes were ICU mortality, ICU and hospital lengths of stay, the proportion of patients discharged home.\nRESULTS: SAH patients with a history of cardiac arrest preceding ICU admission had a higher mortality rate (81.5\\% v 23.3\\%; P {\\textless} 0.0001) and a lower rate of discharge home (4.6\\% v 37.0\\%; P {\\textless} 0.0001) compared with patients with SAH who did not have a cardiac arrest. Among patients with SAH who had a cardiac arrest and survived, 20 of 81 (24.7\\%) were discharged home. In SAH patients with cardiac arrest, having a GCS of 3, the Australian and New Zealand Risk of Death score, and being admitted to ICU for palliative care or organ donation were significant predictors of in-hospital death.\nCONCLUSIONS: Almost one in five SAH patients who had a documented cardiac arrest in the 24 hours preceding ICU admission to an Australian and New Zealand ICU survived to hospital discharge, with around a quarter of these survivors discharged home. The neurological outcomes of these patients are uncertain, and understanding the burden of disability in survivors is an important area for further research.},\n\tlanguage = {eng},\n\tnumber = {3},\n\tjournal = {Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine},\n\tauthor = {Heaney, Jonathan and Paul, Eldho and Pilcher, David and Lin, Caleb and Udy, Andrew and Young, Paul J.},\n\tmonth = sep,\n\tyear = {2020},\n\tpmid = {32900330},\n\tkeywords = {Adult, Australia, Databases, Factual, Female, Heart Arrest, Hospital Mortality, Humans, Intensive Care Units, Length of Stay, Male, Middle Aged, New Zealand, Retrospective Studies, Subarachnoid Hemorrhage},\n\tpages = {237--244},\n}\n\n
\n
\n\n\n
\n OBJECTIVES: To describe the characteristics and outcomes of adults with a subarachnoid haemorrhage (SAH) admitted to Australian and New Zealand intensive care units (ICUs) with a cardiac arrest in the preceding 24 hours. DESIGN: Retrospective cohort study. SETTING: Study data from 144 Australian and New Zealand ICUs were obtained from the Australian and New Zealand Intensive Care Society Centre for Outcome and Resource Evaluation Adult Patient Database. PARTICIPANTS: A total of 439 of 11 047 (3.9%) patients admitted to an ICU with a SAH had a documented cardiac arrest in the 24 hours preceding their ICU admission. The mean age of patients with SAH and a preceding cardiac arrest was 55.3 years (SD, 13.7) and 251 of 439 (57.2%) were female. MAIN OUTCOME MEASURES: The primary outcome of interest was in-hospital mortality. Key secondary outcomes were ICU mortality, ICU and hospital lengths of stay, the proportion of patients discharged home. RESULTS: SAH patients with a history of cardiac arrest preceding ICU admission had a higher mortality rate (81.5% v 23.3%; P \\textless 0.0001) and a lower rate of discharge home (4.6% v 37.0%; P \\textless 0.0001) compared with patients with SAH who did not have a cardiac arrest. Among patients with SAH who had a cardiac arrest and survived, 20 of 81 (24.7%) were discharged home. In SAH patients with cardiac arrest, having a GCS of 3, the Australian and New Zealand Risk of Death score, and being admitted to ICU for palliative care or organ donation were significant predictors of in-hospital death. CONCLUSIONS: Almost one in five SAH patients who had a documented cardiac arrest in the 24 hours preceding ICU admission to an Australian and New Zealand ICU survived to hospital discharge, with around a quarter of these survivors discharged home. The neurological outcomes of these patients are uncertain, and understanding the burden of disability in survivors is an important area for further research.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Effect of Vitamin C, Hydrocortisone, and Thiamine vs Hydrocortisone Alone on Time Alive and Free of Vasopressor Support Among Patients With Septic Shock: The VITAMINS Randomized Clinical Trial.\n \n \n \n \n\n\n \n Fujii, T.; Luethi, N.; Young, P. J.; Frei, D. R.; Eastwood, G. M.; French, C. J.; Deane, A. M.; Shehabi, Y.; Hajjar, L. A.; Oliveira, G.; Udy, A. A.; Orford, N.; Edney, S. J.; Hunt, A. L.; Judd, H. L.; Bitker, L.; Cioccari, L.; Naorungroj, T.; Yanase, F.; Bates, S.; McGain, F.; Hudson, E. P.; Al-Bassam, W.; Dwivedi, D. B.; Peppin, C.; McCracken, P.; Orosz, J.; Bailey, M.; Bellomo, R.; and for the VITAMINS Trial Investigators\n\n\n \n\n\n\n JAMA, 323(5): 423. February 2020.\n \n\n\n\n
\n\n\n\n \n \n \"EffectPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{fujii_effect_2020,\n\ttitle = {Effect of {Vitamin} {C}, {Hydrocortisone}, and {Thiamine} vs {Hydrocortisone} {Alone} on {Time} {Alive} and {Free} of {Vasopressor} {Support} {Among} {Patients} {With} {Septic} {Shock}: {The} {VITAMINS} {Randomized} {Clinical} {Trial}},\n\tvolume = {323},\n\tissn = {0098-7484},\n\tshorttitle = {Effect of {Vitamin} {C}, {Hydrocortisone}, and {Thiamine} vs {Hydrocortisone} {Alone} on {Time} {Alive} and {Free} of {Vasopressor} {Support} {Among} {Patients} {With} {Septic} {Shock}},\n\turl = {https://jamanetwork.com/journals/jama/fullarticle/2759414},\n\tdoi = {10.1001/jama.2019.22176},\n\tlanguage = {en},\n\tnumber = {5},\n\turldate = {2021-05-12},\n\tjournal = {JAMA},\n\tauthor = {Fujii, Tomoko and Luethi, Nora and Young, Paul J. and Frei, Daniel R. and Eastwood, Glenn M. and French, Craig J. and Deane, Adam M. and Shehabi, Yahya and Hajjar, Ludhmila A. and Oliveira, Gisele and Udy, Andrew A. and Orford, Neil and Edney, Samantha J. and Hunt, Anna L. and Judd, Harriet L. and Bitker, Laurent and Cioccari, Luca and Naorungroj, Thummaporn and Yanase, Fumitaka and Bates, Samantha and McGain, Forbes and Hudson, Elizabeth P. and Al-Bassam, Wisam and Dwivedi, Dhiraj Bhatia and Peppin, Chloe and McCracken, Phoebe and Orosz, Judit and Bailey, Michael and Bellomo, Rinaldo and {for the VITAMINS Trial Investigators}},\n\tmonth = feb,\n\tyear = {2020},\n\tpages = {423},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Outcomes Six Months after Delivering 100% or 70% of Enteral Calorie Requirements during Critical Illness (TARGET). A Randomized Controlled Trial.\n \n \n \n \n\n\n \n Deane, A. M.; Little, L.; Bellomo, R.; Chapman, M. J.; Davies, A. R.; Ferrie, S.; Horowitz, M.; Hurford, S.; Lange, K.; Litton, E.; Mackle, D.; O’Connor, S.; Parker, J.; Peake, S. L.; Presneill, J. J.; Ridley, E. J.; Singh, V.; van Haren, F.; Williams, P.; Young, P.; and Iwashyna, T. J.\n\n\n \n\n\n\n American Journal of Respiratory and Critical Care Medicine, 201(7): 814–822. April 2020.\n \n\n\n\n
\n\n\n\n \n \n \"OutcomesPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{deane_outcomes_2020,\n\ttitle = {Outcomes {Six} {Months} after {Delivering} 100\\% or 70\\% of {Enteral} {Calorie} {Requirements} during {Critical} {Illness} ({TARGET}). {A} {Randomized} {Controlled} {Trial}},\n\tvolume = {201},\n\tissn = {1073-449X, 1535-4970},\n\turl = {https://www.atsjournals.org/doi/10.1164/rccm.201909-1810OC},\n\tdoi = {10.1164/rccm.201909-1810OC},\n\tlanguage = {en},\n\tnumber = {7},\n\turldate = {2021-05-12},\n\tjournal = {American Journal of Respiratory and Critical Care Medicine},\n\tauthor = {Deane, Adam M. and Little, Lorraine and Bellomo, Rinaldo and Chapman, Marianne J. and Davies, Andrew R. and Ferrie, Suzie and Horowitz, Michael and Hurford, Sally and Lange, Kylie and Litton, Edward and Mackle, Diane and O’Connor, Stephanie and Parker, Jane and Peake, Sandra L. and Presneill, Jeffrey J. and Ridley, Emma J. and Singh, Vanessa and van Haren, Frank and Williams, Patricia and Young, Paul and Iwashyna, Theodore J.},\n\tmonth = apr,\n\tyear = {2020},\n\tpages = {814--822},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Frailty and outcomes from pneumonia in critical illness: a population-based cohort study.\n \n \n \n \n\n\n \n Darvall, J. N.; Bellomo, R.; Bailey, M.; Paul, E.; Young, P. J.; Rockwood, K.; and Pilcher, D.\n\n\n \n\n\n\n British Journal of Anaesthesia, 125(5): 730–738. November 2020.\n \n\n\n\n
\n\n\n\n \n \n \"FrailtyPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{darvall_frailty_2020,\n\ttitle = {Frailty and outcomes from pneumonia in critical illness: a population-based cohort study},\n\tvolume = {125},\n\tissn = {00070912},\n\tshorttitle = {Frailty and outcomes from pneumonia in critical illness},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S0007091220306425},\n\tdoi = {10.1016/j.bja.2020.07.049},\n\tlanguage = {en},\n\tnumber = {5},\n\turldate = {2021-05-07},\n\tjournal = {British Journal of Anaesthesia},\n\tauthor = {Darvall, Jai N. and Bellomo, Rinaldo and Bailey, Michael and Paul, Eldho and Young, Paul J. and Rockwood, Kenneth and Pilcher, David},\n\tmonth = nov,\n\tyear = {2020},\n\tpages = {730--738},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Characteristics and Outcomes of Critically Ill Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease in Australia and New Zealand.\n \n \n \n \n\n\n \n Berenyi, F.; Steinfort, D. P.; Abdelhamid, Y. A.; Bailey, M. J.; Pilcher, D. V.; Bellomo, R.; Finnis, M. E.; Young, P. J.; and Deane, A. M.\n\n\n \n\n\n\n Annals of the American Thoracic Society, 17(6): 736–745. June 2020.\n \n\n\n\n
\n\n\n\n \n \n \"CharacteristicsPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{berenyi_characteristics_2020,\n\ttitle = {Characteristics and {Outcomes} of {Critically} {Ill} {Patients} with {Acute} {Exacerbation} of {Chronic} {Obstructive} {Pulmonary} {Disease} in {Australia} and {New} {Zealand}},\n\tvolume = {17},\n\tissn = {2329-6933, 2325-6621},\n\turl = {https://www.atsjournals.org/doi/10.1513/AnnalsATS.201911-821OC},\n\tdoi = {10.1513/AnnalsATS.201911-821OC},\n\tlanguage = {en},\n\tnumber = {6},\n\turldate = {2021-05-07},\n\tjournal = {Annals of the American Thoracic Society},\n\tauthor = {Berenyi, Freya and Steinfort, Daniel P. and Abdelhamid, Yasmine Ali and Bailey, Michael J. and Pilcher, David V. and Bellomo, Rinaldo and Finnis, Mark E. and Young, Paul J. and Deane, Adam M.},\n\tmonth = jun,\n\tyear = {2020},\n\tpages = {736--745},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Angiotensin I and angiotensin II concentrations and their ratio in catecholamine-resistant vasodilatory shock.\n \n \n \n \n\n\n \n Bellomo, R.; Wunderink, R. G.; Szerlip, H.; English, S. W.; Busse, L. W.; Deane, A. M.; Khanna, A. K.; McCurdy, M. T.; Ostermann, M.; Young, P. J.; Handisides, D. R.; Chawla, L. S.; Tidmarsh, G. F.; and Albertson, T. E.\n\n\n \n\n\n\n Critical Care, 24(1): 43. December 2020.\n \n\n\n\n
\n\n\n\n \n \n \"AngiotensinPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{bellomo_angiotensin_2020,\n\ttitle = {Angiotensin {I} and angiotensin {II} concentrations and their ratio in catecholamine-resistant vasodilatory shock},\n\tvolume = {24},\n\tissn = {1364-8535},\n\turl = {https://ccforum.biomedcentral.com/articles/10.1186/s13054-020-2733-x},\n\tdoi = {10.1186/s13054-020-2733-x},\n\tabstract = {Abstract\n            \n              Background\n              In patients with vasodilatory shock, plasma concentrations of angiotensin I (ANG I) and II (ANG II) and their ratio may reflect differences in the response to severe vasodilation, provide novel insights into its biology, and predict clinical outcomes. The objective of these protocol prespecified and subsequent post hoc analyses was to assess the epidemiology and outcome associations of plasma ANG I and ANG II levels and their ratio in patients with catecholamine-resistant vasodilatory shock (CRVS) enrolled in the Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) study.\n            \n            \n              Methods\n              We measured ANG I and ANG II levels at baseline, calculated their ratio, and compared these results to values from healthy volunteers (controls). We dichotomized patients according to the median ANG I/II ratio (1.63) and compared demographics, clinical characteristics, and clinical outcomes. We constructed a Cox proportional hazards model to test the independent association of ANG I, ANG II, and their ratio with clinical outcomes.\n            \n            \n              Results\n              \n                Median baseline ANG I level (253 pg/mL [interquartile range (IQR) 72.30–676.00 pg/mL] vs 42 pg/mL [IQR 30.46–87.34 pg/mL] in controls;\n                P\n                 {\\textless}  0.0001) and median ANG I/II ratio (1.63 [IQR 0.98–5.25] vs 0.4 [IQR 0.28–0.64] in controls;\n                P\n                 {\\textless}  0.0001) were elevated, whereas median ANG II levels were similar (84 pg/mL [IQR 23.85–299.50 pg/mL] vs 97 pg/mL [IQR 35.27–181.01 pg/mL] in controls;\n                P\n                 = 0.9895). At baseline, patients with a ratio above the median (≥1.63) had higher ANG I levels (\n                P\n                 {\\textless}  0.0001), lower ANG II levels (\n                P\n                 {\\textless}  0.0001), higher albumin concentrations (\n                P\n                 = 0.007), and greater incidence of recent (within 1 week) exposure to angiotensin-converting enzyme inhibitors (\n                P\n                 {\\textless}  0.00001), and they received a higher norepinephrine-equivalent dose (\n                P\n                 = 0.003). In the placebo group, a baseline ANG I/II ratio {\\textless}1.63 was associated with improved survival (hazard ratio 0.56; 95\\% confidence interval 0.36–0.88;\n                P\n                 = 0.01) on unadjusted analyses.\n              \n            \n            \n              Conclusions\n              Patients with CRVS have elevated ANG I levels and ANG I/II ratios compared with healthy controls. In such patients, a high ANG I/II ratio is associated with greater norepinephrine requirements and is an independent predictor of mortality, thus providing a biological rationale for interventions aimed at its correction.\n            \n            \n              Trial registration\n              \n                ClinicalTrials.gov identifier\n                NCT02338843\n                . Registered 14 January 2015.},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2021-05-07},\n\tjournal = {Critical Care},\n\tauthor = {Bellomo, Rinaldo and Wunderink, Richard G. and Szerlip, Harold and English, Shane W. and Busse, Laurence W. and Deane, Adam M. and Khanna, Ashish K. and McCurdy, Michael T. and Ostermann, Marlies and Young, Paul J. and Handisides, Damian R. and Chawla, Lakhmir S. and Tidmarsh, George F. and Albertson, Timothy E.},\n\tmonth = dec,\n\tyear = {2020},\n\tpages = {43},\n}\n\n
\n
\n\n\n
\n Abstract Background In patients with vasodilatory shock, plasma concentrations of angiotensin I (ANG I) and II (ANG II) and their ratio may reflect differences in the response to severe vasodilation, provide novel insights into its biology, and predict clinical outcomes. The objective of these protocol prespecified and subsequent post hoc analyses was to assess the epidemiology and outcome associations of plasma ANG I and ANG II levels and their ratio in patients with catecholamine-resistant vasodilatory shock (CRVS) enrolled in the Angiotensin II for the Treatment of High-Output Shock (ATHOS-3) study. Methods We measured ANG I and ANG II levels at baseline, calculated their ratio, and compared these results to values from healthy volunteers (controls). We dichotomized patients according to the median ANG I/II ratio (1.63) and compared demographics, clinical characteristics, and clinical outcomes. We constructed a Cox proportional hazards model to test the independent association of ANG I, ANG II, and their ratio with clinical outcomes. Results Median baseline ANG I level (253 pg/mL [interquartile range (IQR) 72.30–676.00 pg/mL] vs 42 pg/mL [IQR 30.46–87.34 pg/mL] in controls; P  \\textless  0.0001) and median ANG I/II ratio (1.63 [IQR 0.98–5.25] vs 0.4 [IQR 0.28–0.64] in controls; P  \\textless  0.0001) were elevated, whereas median ANG II levels were similar (84 pg/mL [IQR 23.85–299.50 pg/mL] vs 97 pg/mL [IQR 35.27–181.01 pg/mL] in controls; P  = 0.9895). At baseline, patients with a ratio above the median (≥1.63) had higher ANG I levels ( P  \\textless  0.0001), lower ANG II levels ( P  \\textless  0.0001), higher albumin concentrations ( P  = 0.007), and greater incidence of recent (within 1 week) exposure to angiotensin-converting enzyme inhibitors ( P  \\textless  0.00001), and they received a higher norepinephrine-equivalent dose ( P  = 0.003). In the placebo group, a baseline ANG I/II ratio \\textless1.63 was associated with improved survival (hazard ratio 0.56; 95% confidence interval 0.36–0.88; P  = 0.01) on unadjusted analyses. Conclusions Patients with CRVS have elevated ANG I levels and ANG I/II ratios compared with healthy controls. In such patients, a high ANG I/II ratio is associated with greater norepinephrine requirements and is an independent predictor of mortality, thus providing a biological rationale for interventions aimed at its correction. Trial registration ClinicalTrials.gov identifier NCT02338843 . Registered 14 January 2015.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Neuromuscular blockade in patients with ARDS: a rapid practice guideline.\n \n \n \n \n\n\n \n Alhazzani, W.; Belley-Cote, E.; Møller, M. H.; Angus, D. C.; Papazian, L.; Arabi, Y. M.; Citerio, G.; Connolly, B.; Denehy, L.; Fox-Robichaud, A.; Hough, C. L.; Laake, J. H.; Machado, F. R.; Ostermann, M.; Piraino, T.; Sharif, S.; Szczeklik, W.; Young, P. J.; Gouskos, A.; Kiedrowski, K.; and Burns, K. E. A.\n\n\n \n\n\n\n Intensive Care Medicine, 46(11): 1977–1986. November 2020.\n \n\n\n\n
\n\n\n\n \n \n \"NeuromuscularPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{alhazzani_neuromuscular_2020,\n\ttitle = {Neuromuscular blockade in patients with {ARDS}: a rapid practice guideline},\n\tvolume = {46},\n\tissn = {0342-4642, 1432-1238},\n\tshorttitle = {Neuromuscular blockade in patients with {ARDS}},\n\turl = {http://link.springer.com/10.1007/s00134-020-06227-8},\n\tdoi = {10.1007/s00134-020-06227-8},\n\tlanguage = {en},\n\tnumber = {11},\n\turldate = {2021-05-05},\n\tjournal = {Intensive Care Medicine},\n\tauthor = {Alhazzani, Waleed and Belley-Cote, E. and Møller, M. H. and Angus, D. C. and Papazian, L. and Arabi, Y. M. and Citerio, G. and Connolly, B. and Denehy, L. and Fox-Robichaud, A. and Hough, C. L. and Laake, J. H. and Machado, F. R. and Ostermann, M. and Piraino, T. and Sharif, S. and Szczeklik, W. and Young, P. J. and Gouskos, A. and Kiedrowski, K. and Burns, K. E. A.},\n\tmonth = nov,\n\tyear = {2020},\n\tpages = {1977--1986},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n The REMAP-CAP (Randomized Embedded Multifactorial Adaptive Platform for Community-acquired Pneumonia) Study. Rationale and Design.\n \n \n \n \n\n\n \n Angus, D. C.; Berry, S.; Lewis, R. J.; Al-Beidh, F.; Arabi, Y.; van Bentum-Puijk, W.; Bhimani, Z.; Bonten, M.; Broglio, K.; Brunkhorst, F.; Cheng, A. C.; Chiche, J.; De Jong, M.; Detry, M.; Goossens, H.; Gordon, A.; Green, C.; Higgins, A. M.; Hullegie, S. J.; Kruger, P.; Lamontagne, F.; Litton, E.; Marshall, J.; McGlothlin, A.; McGuinness, S.; Mouncey, P.; Murthy, S.; Nichol, A.; O’Neill, G. K.; Parke, R.; Parker, J.; Rohde, G.; Rowan, K.; Turner, A.; Young, P.; Derde, L.; McArthur, C.; and Webb, S. A.\n\n\n \n\n\n\n Annals of the American Thoracic Society, 17(7): 879–891. July 2020.\n \n\n\n\n
\n\n\n\n \n \n \"ThePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{angus_remap-cap_2020,\n\ttitle = {The {REMAP}-{CAP} ({Randomized} {Embedded} {Multifactorial} {Adaptive} {Platform} for {Community}-acquired {Pneumonia}) {Study}. {Rationale} and {Design}},\n\tvolume = {17},\n\tissn = {2329-6933, 2325-6621},\n\turl = {https://www.atsjournals.org/doi/10.1513/AnnalsATS.202003-192SD},\n\tdoi = {10.1513/AnnalsATS.202003-192SD},\n\tlanguage = {en},\n\tnumber = {7},\n\turldate = {2021-04-28},\n\tjournal = {Annals of the American Thoracic Society},\n\tauthor = {Angus, Derek C. and Berry, Scott and Lewis, Roger J. and Al-Beidh, Farah and Arabi, Yaseen and van Bentum-Puijk, Wilma and Bhimani, Zahra and Bonten, Marc and Broglio, Kristine and Brunkhorst, Frank and Cheng, Allen C. and Chiche, Jean-Daniel and De Jong, Menno and Detry, Michelle and Goossens, Herman and Gordon, Anthony and Green, Cameron and Higgins, Alisa M. and Hullegie, Sebastiaan J. and Kruger, Peter and Lamontagne, Francois and Litton, Edward and Marshall, John and McGlothlin, Anna and McGuinness, Shay and Mouncey, Paul and Murthy, Srinivas and Nichol, Alistair and O’Neill, Genevieve K. and Parke, Rachael and Parker, Jane and Rohde, Gernot and Rowan, Kathryn and Turner, Anne and Young, Paul and Derde, Lennie and McArthur, Colin and Webb, Steven A.},\n\tmonth = jul,\n\tyear = {2020},\n\tpages = {879--891},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Effect of Hydrocortisone on Mortality and Organ Support in Patients With Severe COVID-19: The REMAP-CAP COVID-19 Corticosteroid Domain Randomized Clinical Trial.\n \n \n \n \n\n\n \n The Writing Committee for the REMAP-CAP Investigators; Angus, D. C.; Derde, L.; Al-Beidh, F.; Annane, D.; Arabi, Y.; Beane, A.; van Bentum-Puijk, W.; Berry, L.; Bhimani, Z.; Bonten, M.; Bradbury, C.; Brunkhorst, F.; Buxton, M.; Buzgau, A.; Cheng, A. C.; de Jong, M.; Detry, M.; Estcourt, L.; Fitzgerald, M.; Goossens, H.; Green, C.; Haniffa, R.; Higgins, A. M.; Horvat, C.; Hullegie, S. J.; Kruger, P.; Lamontagne, F.; Lawler, P. R.; Linstrum, K.; Litton, E.; Lorenzi, E.; Marshall, J.; McAuley, D.; McGlothin, A.; McGuinness, S.; McVerry, B.; Montgomery, S.; Mouncey, P.; Murthy, S.; Nichol, A.; Parke, R.; Parker, J.; Rowan, K.; Sanil, A.; Santos, M.; Saunders, C.; Seymour, C.; Turner, A.; van de Veerdonk, F.; Venkatesh, B.; Zarychanski, R.; Berry, S.; Lewis, R. J.; McArthur, C.; Webb, S. A.; and Gordon, A. C.\n\n\n \n\n\n\n JAMA, 324(13): 1317. October 2020.\n \n\n\n\n
\n\n\n\n \n \n \"EffectPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{the_writing_committee_for_the_remap-cap_investigators_effect_2020,\n\ttitle = {Effect of {Hydrocortisone} on {Mortality} and {Organ} {Support} in {Patients} {With} {Severe} {COVID}-19: {The} {REMAP}-{CAP} {COVID}-19 {Corticosteroid} {Domain} {Randomized} {Clinical} {Trial}},\n\tvolume = {324},\n\tissn = {0098-7484},\n\tshorttitle = {Effect of {Hydrocortisone} on {Mortality} and {Organ} {Support} in {Patients} {With} {Severe} {COVID}-19},\n\turl = {https://jamanetwork.com/journals/jama/fullarticle/2770278},\n\tdoi = {10.1001/jama.2020.17022},\n\tlanguage = {en},\n\tnumber = {13},\n\turldate = {2021-04-28},\n\tjournal = {JAMA},\n\tauthor = {{The Writing Committee for the REMAP-CAP Investigators} and Angus, Derek C. and Derde, Lennie and Al-Beidh, Farah and Annane, Djillali and Arabi, Yaseen and Beane, Abigail and van Bentum-Puijk, Wilma and Berry, Lindsay and Bhimani, Zahra and Bonten, Marc and Bradbury, Charlotte and Brunkhorst, Frank and Buxton, Meredith and Buzgau, Adrian and Cheng, Allen C. and de Jong, Menno and Detry, Michelle and Estcourt, Lise and Fitzgerald, Mark and Goossens, Herman and Green, Cameron and Haniffa, Rashan and Higgins, Alisa M. and Horvat, Christopher and Hullegie, Sebastiaan J. and Kruger, Peter and Lamontagne, Francois and Lawler, Patrick R. and Linstrum, Kelsey and Litton, Edward and Lorenzi, Elizabeth and Marshall, John and McAuley, Daniel and McGlothin, Anna and McGuinness, Shay and McVerry, Bryan and Montgomery, Stephanie and Mouncey, Paul and Murthy, Srinivas and Nichol, Alistair and Parke, Rachael and Parker, Jane and Rowan, Kathryn and Sanil, Ashish and Santos, Marlene and Saunders, Christina and Seymour, Christopher and Turner, Anne and van de Veerdonk, Frank and Venkatesh, Balasubramanian and Zarychanski, Ryan and Berry, Scott and Lewis, Roger J. and McArthur, Colin and Webb, Steven A. and Gordon, Anthony C.},\n\tmonth = oct,\n\tyear = {2020},\n\tpages = {1317},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Coagulation abnormalities, bleeding, thrombosis, and management of patients with acute liver failure in Australia and New Zealand.\n \n \n \n \n\n\n \n Warrillow, S.; Fisher, C.; Tibballs, H.; Bailey, M.; McArthur, C.; Lawson‐Smith, P.; Prasad, B.; Anstey, M.; Venkatesh, B.; Dashwood, G.; Walsham, J.; Holt, A.; Wiersema, U.; Gattas, D.; Zoeller, M.; Garcia Alvarez, M.; and Bellomo, R.\n\n\n \n\n\n\n Journal of Gastroenterology and Hepatology, 35(5): 846–854. May 2020.\n Number: 5\n\n\n\n
\n\n\n\n \n \n \"CoagulationPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{warrillow_coagulation_2020,\n\ttitle = {Coagulation abnormalities, bleeding, thrombosis, and management of patients with acute liver failure in {Australia} and {New} {Zealand}},\n\tvolume = {35},\n\tissn = {0815-9319, 1440-1746},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.1111/jgh.14876},\n\tdoi = {10.1111/jgh.14876},\n\tlanguage = {en},\n\tnumber = {5},\n\turldate = {2020-08-23},\n\tjournal = {Journal of Gastroenterology and Hepatology},\n\tauthor = {Warrillow, Stephen and Fisher, Caleb and Tibballs, Heath and Bailey, Michael and McArthur, Colin and Lawson‐Smith, Pia and Prasad, Bheemasenachar and Anstey, Matthew and Venkatesh, Bala and Dashwood, Gemma and Walsham, James and Holt, Andrew and Wiersema, Ubbo and Gattas, David and Zoeller, Matthew and Garcia Alvarez, Mercedes and Bellomo, Rinaldo},\n\tmonth = may,\n\tyear = {2020},\n\tnote = {Number: 5},\n\tpages = {846--854},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Timing of Initiation of Renal-Replacement Therapy in Acute Kidney Injury.\n \n \n \n \n\n\n \n The STARRT-AKI Investigators\n\n\n \n\n\n\n New England Journal of Medicine, 383(3): 240–251. July 2020.\n Number: 3\n\n\n\n
\n\n\n\n \n \n \"TimingPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{the_starrt-aki_investigators_timing_2020,\n\ttitle = {Timing of {Initiation} of {Renal}-{Replacement} {Therapy} in {Acute} {Kidney} {Injury}},\n\tvolume = {383},\n\tissn = {0028-4793, 1533-4406},\n\turl = {http://www.nejm.org/doi/10.1056/NEJMoa2000741},\n\tdoi = {10.1056/NEJMoa2000741},\n\tlanguage = {en},\n\tnumber = {3},\n\turldate = {2020-08-23},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {{The STARRT-AKI Investigators}},\n\tmonth = jul,\n\tyear = {2020},\n\tnote = {Number: 3},\n\tpages = {240--251},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Conservative Oxygen Therapy during Mechanical Ventilation in the ICU.\n \n \n \n \n\n\n \n The ICU-ROX Investigators; Australian, t.; and Group, N. Z. I. C. S. C. T.\n\n\n \n\n\n\n New England Journal of Medicine, 382(11): 989–998. March 2020.\n Number: 11\n\n\n\n
\n\n\n\n \n \n \"ConservativePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{the_icu-rox_investigators_and_the_australian_and_new_zealand_intensive_care_society_clinical_trials_group_conservative_2020,\n\ttitle = {Conservative {Oxygen} {Therapy} during {Mechanical} {Ventilation} in the {ICU}},\n\tvolume = {382},\n\tissn = {0028-4793, 1533-4406},\n\turl = {http://www.nejm.org/doi/10.1056/NEJMoa1903297},\n\tdoi = {10.1056/NEJMoa1903297},\n\tlanguage = {en},\n\tnumber = {11},\n\turldate = {2020-08-23},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {{The ICU-ROX Investigators and the Australian and New Zealand Intensive Care Society Clinical Trials Group}},\n\tmonth = mar,\n\tyear = {2020},\n\tnote = {Number: 11},\n\tpages = {989--998},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Effect of Stress Ulcer Prophylaxis With Proton Pump Inhibitors vs Histamine-2 Receptor Blockers on In-Hospital Mortality Among ICU Patients Receiving Invasive Mechanical Ventilation: The PEPTIC Randomized Clinical Trial.\n \n \n \n \n\n\n \n The PEPTIC Investigators for the Australian; New Zealand Intensive Care Society Clinical Trials Group, A. H. S. C. C. S. C. N.; Group, t. I. C. C. T.; Young, P. J.; Bagshaw, S. M.; Forbes, A. B.; Nichol, A. D.; Wright, S. E.; Bailey, M.; Bellomo, R.; Beasley, R.; Brickell, K.; Eastwood, G. M.; Gattas, D. J.; van Haren, F.; Litton, E.; Mackle, D. M.; McArthur, C. J.; McGuinness, S. P.; Mouncey, P. R.; Navarra, L.; Opgenorth, D.; Pilcher, D.; Saxena, M. K.; Webb, S. A.; Wiley, D.; and Rowan, K. M.\n\n\n \n\n\n\n JAMA, 323(7): 616. February 2020.\n Number: 7\n\n\n\n
\n\n\n\n \n \n \"EffectPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{the_peptic_investigators_for_the_australian_and_new_zealand_intensive_care_society_clinical_trials_group_alberta_health_services_critical_care_strategic_clinical_network_and_the_irish_critical_care_trials_group_effect_2020,\n\ttitle = {Effect of {Stress} {Ulcer} {Prophylaxis} {With} {Proton} {Pump} {Inhibitors} vs {Histamine}-2 {Receptor} {Blockers} on {In}-{Hospital} {Mortality} {Among} {ICU} {Patients} {Receiving} {Invasive} {Mechanical} {Ventilation}: {The} {PEPTIC} {Randomized} {Clinical} {Trial}},\n\tvolume = {323},\n\tissn = {0098-7484},\n\tshorttitle = {Effect of {Stress} {Ulcer} {Prophylaxis} {With} {Proton} {Pump} {Inhibitors} vs {Histamine}-2 {Receptor} {Blockers} on {In}-{Hospital} {Mortality} {Among} {ICU} {Patients} {Receiving} {Invasive} {Mechanical} {Ventilation}},\n\turl = {https://jamanetwork.com/journals/jama/fullarticle/2759412},\n\tdoi = {10.1001/jama.2019.22190},\n\tlanguage = {en},\n\tnumber = {7},\n\turldate = {2020-08-23},\n\tjournal = {JAMA},\n\tauthor = {{The PEPTIC Investigators for the Australian and New Zealand Intensive Care Society Clinical Trials Group, Alberta Health Services Critical Care Strategic Clinical Network, and the Irish Critical Care Trials Group} and Young, Paul J. and Bagshaw, Sean M. and Forbes, Andrew B. and Nichol, Alistair D. and Wright, Stephen E. and Bailey, Michael and Bellomo, Rinaldo and Beasley, Richard and Brickell, Kathy and Eastwood, Glenn M. and Gattas, David J. and van Haren, Frank and Litton, Edward and Mackle, Diane M. and McArthur, Colin J. and McGuinness, Shay P. and Mouncey, Paul R. and Navarra, Leanlove and Opgenorth, Dawn and Pilcher, David and Saxena, Manoj K. and Webb, Steve A. and Wiley, Daisy and Rowan, Kathryn M.},\n\tmonth = feb,\n\tyear = {2020},\n\tnote = {Number: 7},\n\tpages = {616},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2019\n \n \n (24)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n Is sepsis treatment heating up?.\n \n \n \n\n\n \n Young, P. J.\n\n\n \n\n\n\n Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 21(2): 85–86. June 2019.\n Number: 2\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{young_is_2019,\n\ttitle = {Is sepsis treatment heating up?},\n\tvolume = {21},\n\tissn = {1441-2772},\n\tlanguage = {eng},\n\tnumber = {2},\n\tjournal = {Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine},\n\tauthor = {Young, Paul J.},\n\tmonth = jun,\n\tyear = {2019},\n\tpmid = {31142237},\n\tnote = {Number: 2},\n\tkeywords = {Heating, Humans, Sepsis},\n\tpages = {85--86},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n When less is more in the active management of elevated body temperature of ICU patients.\n \n \n \n \n\n\n \n Young, P. J.; and Prescott, H. C.\n\n\n \n\n\n\n Intensive Care Medicine, 45(9): 1275–1278. September 2019.\n Number: 9\n\n\n\n
\n\n\n\n \n \n \"WhenPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{young_when_2019,\n\ttitle = {When less is more in the active management of elevated body temperature of {ICU} patients},\n\tvolume = {45},\n\tissn = {0342-4642, 1432-1238},\n\turl = {http://link.springer.com/10.1007/s00134-019-05668-0},\n\tdoi = {10.1007/s00134-019-05668-0},\n\tlanguage = {en},\n\tnumber = {9},\n\turldate = {2020-08-23},\n\tjournal = {Intensive Care Medicine},\n\tauthor = {Young, Paul J. and Prescott, Hallie C.},\n\tmonth = sep,\n\tyear = {2019},\n\tnote = {Number: 9},\n\tpages = {1275--1278},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Vasopressin in septic shock: what we know and where to next?.\n \n \n \n \n\n\n \n Young, P. J.; Delaney, A.; and Venkatesh, B.\n\n\n \n\n\n\n Intensive Care Medicine, 45(6): 902–903. June 2019.\n Number: 6\n\n\n\n
\n\n\n\n \n \n \"VasopressinPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{young_vasopressin_2019,\n\ttitle = {Vasopressin in septic shock: what we know and where to next?},\n\tvolume = {45},\n\tissn = {0342-4642, 1432-1238},\n\tshorttitle = {Vasopressin in septic shock},\n\turl = {http://link.springer.com/10.1007/s00134-019-05642-w},\n\tdoi = {10.1007/s00134-019-05642-w},\n\tlanguage = {en},\n\tnumber = {6},\n\turldate = {2020-08-23},\n\tjournal = {Intensive Care Medicine},\n\tauthor = {Young, Paul J. and Delaney, Anthony and Venkatesh, Balasubramanian},\n\tmonth = jun,\n\tyear = {2019},\n\tnote = {Number: 6},\n\tpages = {902--903},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Balanced Crystalloids or 0.9% Saline in Sepsis. Beyond Reasonable Doubt?.\n \n \n \n \n\n\n \n Young, P. J.\n\n\n \n\n\n\n American Journal of Respiratory and Critical Care Medicine, 200(12): 1456–1458. December 2019.\n Number: 12\n\n\n\n
\n\n\n\n \n \n \"BalancedPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{young_balanced_2019,\n\ttitle = {Balanced {Crystalloids} or 0.9\\% {Saline} in {Sepsis}. {Beyond} {Reasonable} {Doubt}?},\n\tvolume = {200},\n\tissn = {1073-449X, 1535-4970},\n\turl = {https://www.atsjournals.org/doi/10.1164/rccm.201908-1669ED},\n\tdoi = {10.1164/rccm.201908-1669ED},\n\tlanguage = {en},\n\tnumber = {12},\n\turldate = {2020-08-23},\n\tjournal = {American Journal of Respiratory and Critical Care Medicine},\n\tauthor = {Young, Paul J.},\n\tmonth = dec,\n\tyear = {2019},\n\tnote = {Number: 12},\n\tpages = {1456--1458},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Fever control in critically ill adults. An individual patient data meta-analysis of randomised controlled trials.\n \n \n \n \n\n\n \n Young, P. J.; Bellomo, R.; Bernard, G. R.; Niven, D. J.; Schortgen, F.; Saxena, M.; Beasley, R.; and Weatherall, M.\n\n\n \n\n\n\n Intensive Care Medicine, 45(4): 468–476. April 2019.\n Number: 4\n\n\n\n
\n\n\n\n \n \n \"FeverPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{young_fever_2019,\n\ttitle = {Fever control in critically ill adults. {An} individual patient data meta-analysis of randomised controlled trials},\n\tvolume = {45},\n\tissn = {0342-4642, 1432-1238},\n\turl = {http://link.springer.com/10.1007/s00134-019-05553-w},\n\tdoi = {10.1007/s00134-019-05553-w},\n\tlanguage = {en},\n\tnumber = {4},\n\turldate = {2020-08-23},\n\tjournal = {Intensive Care Medicine},\n\tauthor = {Young, Paul J. and Bellomo, Rinaldo and Bernard, Gordon R. and Niven, Daniel J. and Schortgen, Frederique and Saxena, Manoj and Beasley, Richard and Weatherall, Mark},\n\tmonth = apr,\n\tyear = {2019},\n\tnote = {Number: 4},\n\tpages = {468--476},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n O2, do we know what to do?.\n \n \n \n\n\n \n Young, P. J.; Bagshaw, S. M.; Bailey, M.; Bellomo, R.; Mackle, D.; Pilcher, D.; Landoni, G.; Nichol, A.; and Martin, D.\n\n\n \n\n\n\n Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 21(4): 230–232. December 2019.\n Number: 4\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n\n\n\n
\n 
@article{young_o2_2019,\n\ttitle = {O2, do we know what to do?},\n\tvolume = {21},\n\tissn = {1441-2772},\n\tlanguage = {eng},\n\tnumber = {4},\n\tjournal = {Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine},\n\tauthor = {Young, Paul J. and Bagshaw, Sean M. and Bailey, Michael and Bellomo, Rinaldo and Mackle, Diane and Pilcher, David and Landoni, Giovanni and Nichol, Alistair and Martin, Daniel},\n\tmonth = dec,\n\tyear = {2019},\n\tpmid = {31778627},\n\tnote = {Number: 4},\n\tkeywords = {Humans, Oxygen},\n\tpages = {230--232},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n The Risk of Hyperoxemia in ICU Patients. Much Ado About O2.\n \n \n \n\n\n \n Young, P. J.; and Bellomo, R.\n\n\n \n\n\n\n American Journal of Respiratory and Critical Care Medicine, 200(11): 1333–1335. 2019.\n Number: 11\n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{young_risk_2019,\n\ttitle = {The {Risk} of {Hyperoxemia} in {ICU} {Patients}. {Much} {Ado} {About} {O2}},\n\tvolume = {200},\n\tissn = {1535-4970},\n\tdoi = {10.1164/rccm.201909-1751ED},\n\tlanguage = {eng},\n\tnumber = {11},\n\tjournal = {American Journal of Respiratory and Critical Care Medicine},\n\tauthor = {Young, Paul J. and Bellomo, Rinaldo},\n\tyear = {2019},\n\tpmid = {31526323},\n\tpmcid = {PMC6884040},\n\tnote = {Number: 11},\n\tkeywords = {Blood Gas Analysis, Cohort Studies, Critical Illness, Humans, Intensive Care Units, Oxygen},\n\tpages = {1333--1335},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Characteristics, management and outcomes of patients with acute liver failure admitted to Australasian intensive care units.\n \n \n \n\n\n \n Warrillow, S.; Tibballs, H.; Bailey, M.; McArthur, C.; Lawson-Smith, P.; Prasad, B.; Anstey, M.; Venkatesh, B.; Dashwood, G.; Walsham, J.; Holt, A.; Wiersema, U.; Gattas, D.; Zoeller, M.; Garcia Alvarez, M.; Bellomo, R.; and Australasian Management of Acute Liver Failure Investigators (AMALFI)\n\n\n \n\n\n\n Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 21(3): 188–199. September 2019.\n Number: 3\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{warrillow_characteristics_2019,\n\ttitle = {Characteristics, management and outcomes of patients with acute liver failure admitted to {Australasian} intensive care units},\n\tvolume = {21},\n\tissn = {1441-2772},\n\tabstract = {OBJECTIVE: Acute liver failure (ALF) leads to severe illness and usually requires admission to the intensive care unit (ICU). Despite its importance, little is known about patients with ALF in Australia and New Zealand.\nDESIGN: Binational observational study to evaluate the aetiology, baseline characteristics, patterns of illness, management, and outcomes for patients with ALF admitted to Australian and New Zealand ICUs.\nSETTING: All six Australian and New Zealand ICUs in liver transplant centres submitted de-identified data for ten or more consecutive patients with ALF. Data were obtained from the clinical record and included baseline characteristics, aetiology, mode of presentation, illness severity, markers of liver failure, critical care interventions, utilisation of transplantation, and hospital outcome.\nRESULTS: We studied 62 patients with ALF. Paracetamol overdose (POD) was the underlying cause of ALF in 53\\% of patients (33/62), with staggered ingestion in 42\\% of patients (14/33). Among patients with POD, 70\\% (23/33) were young women, most had psychiatric diagnoses, and most presented relatively early with overt liver failure. This group were transplanted in only 6\\% of cases (2/33) and had an overall mortality of 24\\% (8/33). The remaining patients with ALF had less common conditions, such as hepatitis B and non-paracetamol drug-induced ALF. These patients presented later and exhibited less extreme evidence of acute hepatic necrosis. Transplantation was performed in 38\\% of patients (11/29) in this subgroup. The mortality of nontransplanted non-POD patients was 56\\% (10/18). Illness severity at ICU admission, initial requirement for organ support therapies and length of hospital stay were similar between patients with POD and non-POD ALF.\nCONCLUSION: POD is the major cause of ALF in Australian and New Zealand liver transplant centres and is a unique and separate form of ALF. It has a much lower associated mortality and treatment with liver transplantation than non-POD ALF. Non-POD patients have a poor prognosis in the absence of transplantation.},\n\tlanguage = {eng},\n\tnumber = {3},\n\tjournal = {Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine},\n\tauthor = {Warrillow, Stephen and Tibballs, Heath and Bailey, Michael and McArthur, Colin and Lawson-Smith, Pia and Prasad, Bheemasenachar and Anstey, Matthew and Venkatesh, Balasubramanian and Dashwood, Gemma and Walsham, James and Holt, Andrew and Wiersema, Ubbo and Gattas, David and Zoeller, Matthew and Garcia Alvarez, Mercedes and Bellomo, Rinaldo and {Australasian Management of Acute Liver Failure Investigators (AMALFI)}},\n\tmonth = sep,\n\tyear = {2019},\n\tpmid = {31462206},\n\tnote = {Number: 3},\n\tkeywords = {Acetaminophen, Adolescent, Adult, Analgesics, Non-Narcotic, Australia, Drug Overdose, Female, Humans, Intensive Care Units, Liver Failure, Acute, Liver Transplantation, Mental Disorders, New Zealand, Treatment Outcome, Young Adult},\n\tpages = {188--199},\n}\n\n
\n
\n\n\n
\n OBJECTIVE: Acute liver failure (ALF) leads to severe illness and usually requires admission to the intensive care unit (ICU). Despite its importance, little is known about patients with ALF in Australia and New Zealand. DESIGN: Binational observational study to evaluate the aetiology, baseline characteristics, patterns of illness, management, and outcomes for patients with ALF admitted to Australian and New Zealand ICUs. SETTING: All six Australian and New Zealand ICUs in liver transplant centres submitted de-identified data for ten or more consecutive patients with ALF. Data were obtained from the clinical record and included baseline characteristics, aetiology, mode of presentation, illness severity, markers of liver failure, critical care interventions, utilisation of transplantation, and hospital outcome. RESULTS: We studied 62 patients with ALF. Paracetamol overdose (POD) was the underlying cause of ALF in 53% of patients (33/62), with staggered ingestion in 42% of patients (14/33). Among patients with POD, 70% (23/33) were young women, most had psychiatric diagnoses, and most presented relatively early with overt liver failure. This group were transplanted in only 6% of cases (2/33) and had an overall mortality of 24% (8/33). The remaining patients with ALF had less common conditions, such as hepatitis B and non-paracetamol drug-induced ALF. These patients presented later and exhibited less extreme evidence of acute hepatic necrosis. Transplantation was performed in 38% of patients (11/29) in this subgroup. The mortality of nontransplanted non-POD patients was 56% (10/18). Illness severity at ICU admission, initial requirement for organ support therapies and length of hospital stay were similar between patients with POD and non-POD ALF. CONCLUSION: POD is the major cause of ALF in Australian and New Zealand liver transplant centres and is a unique and separate form of ALF. It has a much lower associated mortality and treatment with liver transplantation than non-POD ALF. Non-POD patients have a poor prognosis in the absence of transplantation.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Study protocol: NITric oxide during cardiopulmonary bypass to improve Recovery in Infants with Congenital heart defects (NITRIC trial): a randomised controlled trial.\n \n \n \n \n\n\n \n Schlapbach, L. J; Horton, S. B.; Long, D. A.; Beca, J.; Erickson, S.; Festa, M.; d’Udekem , Y.; Alphonso, N.; Winlaw, D.; Johnson, K.; Delzoppo, C.; van Loon, K.; Gannon, B; Fooken, J.; Blumenthal, A.; Young, P.; Jones, M.; Butt, W.; and Schibler, A.\n\n\n \n\n\n\n BMJ Open, 9(8): e026664. August 2019.\n Number: 8\n\n\n\n
\n\n\n\n \n \n \"StudyPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{schlapbach_study_2019,\n\ttitle = {Study protocol: {NITric} oxide during cardiopulmonary bypass to improve {Recovery} in {Infants} with {Congenital} heart defects ({NITRIC} trial): a randomised controlled trial},\n\tvolume = {9},\n\tissn = {2044-6055, 2044-6055},\n\tshorttitle = {Study protocol},\n\turl = {http://bmjopen.bmj.com/lookup/doi/10.1136/bmjopen-2018-026664},\n\tdoi = {10.1136/bmjopen-2018-026664},\n\tabstract = {Introduction\n              Congenital heart disease (CHD) is a major cause of infant mortality. Many infants with CHD require corrective surgery with most operations requiring cardiopulmonary bypass (CPB). CPB triggers a systemic inflammatory response which is associated with low cardiac output syndrome (LCOS), postoperative morbidity and mortality. Delivery of nitric oxide (NO) into CPB circuits can provide myocardial protection and reduce bypass-induced inflammation, leading to less LCOS and improved recovery. We hypothesised that using NO during CPB increases ventilator-free days (VFD) (the number of days patients spend alive and free from invasive mechanical ventilation up until day 28) compared with standard care. Here, we describe the NITRIC trial protocol.\n            \n            \n              Methods and analysis\n              The NITRIC trial is a randomised, double-blind, controlled, parallel-group, two-sided superiority trial to be conducted in six paediatric cardiac surgical centres. One thousand three-hundred and twenty infants {\\textless}2 years of age undergoing cardiac surgery with CPB will be randomly assigned to NO at 20 ppm administered into the CPB oxygenator for the duration of CPB or standard care (no NO) in a 1:1 ratio with stratification by age ({\\textless}6 and ≥6 weeks), single ventricle physiology (Y/N) and study centre. The primary outcome will be VFD to day 28. Secondary outcomes include a composite of LCOS, need for extracorporeal membrane oxygenation or death within 28 days of surgery; length of stay in intensive care and in hospital; and, healthcare costs. Analyses will be conducted on an intention-to-treat basis. Preplanned secondary analyses will investigate the impact of NO on host inflammatory profiles postsurgery.\n            \n            \n              Ethics and dissemination\n              The study has ethical approval (HREC/17/QRCH/43, dated 26 April 2017), is registered in the Australian New Zealand Clinical Trials Registry (ACTRN12617000821392) and commenced recruitment in July 2017. The primary manuscript will be submitted for publication in a peer-reviewed journal.\n            \n            \n              Trial registration number\n              ACTRN12617000821392},\n\tlanguage = {en},\n\tnumber = {8},\n\turldate = {2020-08-23},\n\tjournal = {BMJ Open},\n\tauthor = {Schlapbach, Luregn J and Horton, Stephen Brian and Long, Debbie Amanda and Beca, John and Erickson, Simon and Festa, Marino and d’Udekem, Yves and Alphonso, Nelson and Winlaw, David and Johnson, Kerry and Delzoppo, Carmel and van Loon, Kim and Gannon, B and Fooken, Jonas and Blumenthal, Antje and Young, Paul and Jones, Mark and Butt, Warwick and Schibler, Andreas},\n\tmonth = aug,\n\tyear = {2019},\n\tnote = {Number: 8},\n\tpages = {e026664},\n}\n\n
\n
\n\n\n
\n Introduction Congenital heart disease (CHD) is a major cause of infant mortality. Many infants with CHD require corrective surgery with most operations requiring cardiopulmonary bypass (CPB). CPB triggers a systemic inflammatory response which is associated with low cardiac output syndrome (LCOS), postoperative morbidity and mortality. Delivery of nitric oxide (NO) into CPB circuits can provide myocardial protection and reduce bypass-induced inflammation, leading to less LCOS and improved recovery. We hypothesised that using NO during CPB increases ventilator-free days (VFD) (the number of days patients spend alive and free from invasive mechanical ventilation up until day 28) compared with standard care. Here, we describe the NITRIC trial protocol. Methods and analysis The NITRIC trial is a randomised, double-blind, controlled, parallel-group, two-sided superiority trial to be conducted in six paediatric cardiac surgical centres. One thousand three-hundred and twenty infants \\textless2 years of age undergoing cardiac surgery with CPB will be randomly assigned to NO at 20 ppm administered into the CPB oxygenator for the duration of CPB or standard care (no NO) in a 1:1 ratio with stratification by age (\\textless6 and ≥6 weeks), single ventricle physiology (Y/N) and study centre. The primary outcome will be VFD to day 28. Secondary outcomes include a composite of LCOS, need for extracorporeal membrane oxygenation or death within 28 days of surgery; length of stay in intensive care and in hospital; and, healthcare costs. Analyses will be conducted on an intention-to-treat basis. Preplanned secondary analyses will investigate the impact of NO on host inflammatory profiles postsurgery. Ethics and dissemination The study has ethical approval (HREC/17/QRCH/43, dated 26 April 2017), is registered in the Australian New Zealand Clinical Trials Registry (ACTRN12617000821392) and commenced recruitment in July 2017. The primary manuscript will be submitted for publication in a peer-reviewed journal. Trial registration number ACTRN12617000821392\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n A randomized controlled feasibility trial of paracetamol during febrile neutropenia in hemato-oncology patients.\n \n \n \n \n\n\n \n Weinkove, R.; Bowden, E.; Wood, C.; Campion, V.; Carter, J.; Hall, R.; Weatherall, M.; Beasley, R.; and Young, P.\n\n\n \n\n\n\n Leukemia & Lymphoma, 60(6): 1540–1547. May 2019.\n Number: 6\n\n\n\n
\n\n\n\n \n \n \"APaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{weinkove_randomized_2019,\n\ttitle = {A randomized controlled feasibility trial of paracetamol during febrile neutropenia in hemato-oncology patients},\n\tvolume = {60},\n\tissn = {1042-8194, 1029-2403},\n\turl = {https://www.tandfonline.com/doi/full/10.1080/10428194.2018.1538512},\n\tdoi = {10.1080/10428194.2018.1538512},\n\tlanguage = {en},\n\tnumber = {6},\n\turldate = {2020-08-23},\n\tjournal = {Leukemia \\& Lymphoma},\n\tauthor = {Weinkove, Robert and Bowden, Emily and Wood, Catherine and Campion, Victoria and Carter, John and Hall, Richard and Weatherall, Mark and Beasley, Richard and Young, Paul},\n\tmonth = may,\n\tyear = {2019},\n\tnote = {Number: 6},\n\tpages = {1540--1547},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Characteristics and outcomes of patients with acute liver failure admitted to Australian and New Zealand intensive care units.\n \n \n \n \n\n\n \n Warrillow, S.; Bailey, M.; Pilcher, D.; Kazemi, A.; McArthur, C.; Young, P.; and Bellomo, R.\n\n\n \n\n\n\n Internal Medicine Journal, 49(7): 874–885. July 2019.\n Number: 7\n\n\n\n
\n\n\n\n \n \n \"CharacteristicsPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{warrillow_characteristics_2019-1,\n\ttitle = {Characteristics and outcomes of patients with acute liver failure admitted to {Australian} and {New} {Zealand} intensive care units},\n\tvolume = {49},\n\tissn = {1444-0903, 1445-5994},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.1111/imj.14167},\n\tdoi = {10.1111/imj.14167},\n\tlanguage = {en},\n\tnumber = {7},\n\turldate = {2020-08-23},\n\tjournal = {Internal Medicine Journal},\n\tauthor = {Warrillow, Stephen and Bailey, Michael and Pilcher, David and Kazemi, Alex and McArthur, Colin and Young, Paul and Bellomo, Rinaldo},\n\tmonth = jul,\n\tyear = {2019},\n\tnote = {Number: 7},\n\tpages = {874--885},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n What Happens to Nutrition Intake in the Post-Intensive Care Unit Hospitalization Period? An Observational Cohort Study in Critically Ill Adults.\n \n \n \n \n\n\n \n Ridley, E. J.; Parke, R. L.; Davies, A. R.; Bailey, M.; Hodgson, C.; Deane, A. M.; McGuinness, S.; and Cooper, D. J.\n\n\n \n\n\n\n Journal of Parenteral and Enteral Nutrition, 43(1): 88–95. January 2019.\n Number: 1\n\n\n\n
\n\n\n\n \n \n \"WhatPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{ridley_what_2019,\n\ttitle = {What {Happens} to {Nutrition} {Intake} in the {Post}-{Intensive} {Care} {Unit} {Hospitalization} {Period}? {An} {Observational} {Cohort} {Study} in {Critically} {Ill} {Adults}},\n\tvolume = {43},\n\tissn = {01486071},\n\tshorttitle = {What {Happens} to {Nutrition} {Intake} in the {Post}-{Intensive} {Care} {Unit} {Hospitalization} {Period}?},\n\turl = {http://doi.wiley.com/10.1002/jpen.1196},\n\tdoi = {10.1002/jpen.1196},\n\tlanguage = {en},\n\tnumber = {1},\n\turldate = {2020-08-23},\n\tjournal = {Journal of Parenteral and Enteral Nutrition},\n\tauthor = {Ridley, Emma J. and Parke, Rachael L. and Davies, Andrew R. and Bailey, Michael and Hodgson, Carol and Deane, Adam M. and McGuinness, Shay and Cooper, D. James},\n\tmonth = jan,\n\tyear = {2019},\n\tnote = {Number: 1},\n\tpages = {88--95},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Early dysglycemia and mortality in traumatic brain injury and subarachnoid hemorrhage.\n \n \n \n \n\n\n \n Pappacena, S.; Bailey, M.; Cabrini, L.; Landoni, G.; Udy, A.; Pilcher, D. V.; Young, P.; and Bellomo, R.\n\n\n \n\n\n\n Minerva Anestesiologica, 85(8). July 2019.\n Number: 8\n\n\n\n
\n\n\n\n \n \n \"EarlyPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{pappacena_early_2019,\n\ttitle = {Early dysglycemia and mortality in traumatic brain injury and subarachnoid hemorrhage},\n\tvolume = {85},\n\tissn = {03759393, 18271596},\n\turl = {https://www.minervamedica.it/index2.php?show=R02Y2019N08A0830},\n\tdoi = {10.23736/S0375-9393.19.13307-X},\n\tnumber = {8},\n\turldate = {2020-08-23},\n\tjournal = {Minerva Anestesiologica},\n\tauthor = {Pappacena, Simone and Bailey, Michael and Cabrini, Luca and Landoni, Giovanni and Udy, Andrew and Pilcher, David V. and Young, Paul and Bellomo, Rinaldo},\n\tmonth = jul,\n\tyear = {2019},\n\tnote = {Number: 8},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Treatable traits: a new paradigm for 21st century management of chronic airway diseases: Treatable Traits Down Under International Workshop report.\n \n \n \n \n\n\n \n McDonald, V. M.; Fingleton, J.; Agusti, A.; Hiles, S. A.; Clark, V. L.; Holland, A. E.; Marks, G. B.; Bardin, P. P.; Beasley, R.; Pavord, I. D.; Wark, P. A.; and Gibson, P. G.\n\n\n \n\n\n\n European Respiratory Journal, 53(5): 1802058. May 2019.\n Number: 5\n\n\n\n
\n\n\n\n \n \n \"TreatablePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{mcdonald_treatable_2019,\n\ttitle = {Treatable traits: a new paradigm for 21st century management of chronic airway diseases: {Treatable} {Traits} {Down} {Under} {International} {Workshop} report},\n\tvolume = {53},\n\tissn = {0903-1936, 1399-3003},\n\tshorttitle = {Treatable traits},\n\turl = {http://erj.ersjournals.com/lookup/doi/10.1183/13993003.02058-2018},\n\tdoi = {10.1183/13993003.02058-2018},\n\tabstract = {“Treatable traits” have been proposed as a new paradigm for the management of airway diseases, particularly complex disease, which aims to apply personalised medicine to each individual to improve outcomes. Moving new treatment approaches from concepts to practice is challenging, but necessary. In an effort to accelerate progress in research and practice relating to the treatable traits approach, the Treatable Traits Down Under International Workshop was convened in Melbourne, Australia in May 2018. Here, we report the key concepts and research questions that emerged in discussions during the meeting. We propose a programme of research that involves gaining international consensus on candidate traits, recognising the prevalence of traits, and identifying a potential hierarchy of traits based on their clinical impact and responsiveness to treatment. We also reflect on research methods and designs that can generate new knowledge related to efficacy of the treatable traits approach and consider multidisciplinary models of care that may aid its implementation into practice.},\n\tlanguage = {en},\n\tnumber = {5},\n\turldate = {2020-08-23},\n\tjournal = {European Respiratory Journal},\n\tauthor = {McDonald, Vanessa M. and Fingleton, James and Agusti, Alvar and Hiles, Sarah A. and Clark, Vanessa L. and Holland, Anne E. and Marks, Guy B. and Bardin, Philip P. and Beasley, Richard and Pavord, Ian D. and Wark, Peter A.B. and Gibson, Peter G.},\n\tmonth = may,\n\tyear = {2019},\n\tnote = {Number: 5},\n\tpages = {1802058},\n}\n\n
\n
\n\n\n
\n “Treatable traits” have been proposed as a new paradigm for the management of airway diseases, particularly complex disease, which aims to apply personalised medicine to each individual to improve outcomes. Moving new treatment approaches from concepts to practice is challenging, but necessary. In an effort to accelerate progress in research and practice relating to the treatable traits approach, the Treatable Traits Down Under International Workshop was convened in Melbourne, Australia in May 2018. Here, we report the key concepts and research questions that emerged in discussions during the meeting. We propose a programme of research that involves gaining international consensus on candidate traits, recognising the prevalence of traits, and identifying a potential hierarchy of traits based on their clinical impact and responsiveness to treatment. We also reflect on research methods and designs that can generate new knowledge related to efficacy of the treatable traits approach and consider multidisciplinary models of care that may aid its implementation into practice.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Trauma‐related admissions to intensive care units in Australia: the influence of Indigenous status on outcomes.\n \n \n \n \n\n\n \n Magee, F.; Wilson, A.; Bailey, M. J; Pilcher, D.; Secombe, P. J; Young, P.; and Bellomo, R.\n\n\n \n\n\n\n Medical Journal of Australia, 210(11): 493–498. June 2019.\n Number: 11\n\n\n\n
\n\n\n\n \n \n \"Trauma‐relatedPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{magee_traumarelated_2019,\n\ttitle = {Trauma‐related admissions to intensive care units in {Australia}: the influence of {Indigenous} status on outcomes},\n\tvolume = {210},\n\tissn = {0025-729X, 1326-5377},\n\tshorttitle = {Trauma‐related admissions to intensive care units in {Australia}},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.5694/mja2.12028},\n\tdoi = {10.5694/mja2.12028},\n\tlanguage = {en},\n\tnumber = {11},\n\turldate = {2020-08-23},\n\tjournal = {Medical Journal of Australia},\n\tauthor = {Magee, Fraser and Wilson, Anthony and Bailey, Michael J and Pilcher, David and Secombe, Paul J and Young, Paul and Bellomo, Rinaldo},\n\tmonth = jun,\n\tyear = {2019},\n\tnote = {Number: 11},\n\tpages = {493--498},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Research nurses in New Zealand intensive care units: A qualitative descriptive study.\n \n \n \n \n\n\n \n Mackle, D.; and Nelson, K.\n\n\n \n\n\n\n Australian Critical Care, 32(2): 148–154. March 2019.\n Number: 2\n\n\n\n
\n\n\n\n \n \n \"ResearchPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n  \n \n 1 download\n \n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{mackle_research_2019,\n\ttitle = {Research nurses in {New} {Zealand} intensive care units: {A} qualitative descriptive study},\n\tvolume = {32},\n\tissn = {10367314},\n\tshorttitle = {Research nurses in {New} {Zealand} intensive care units},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S1036731417303399},\n\tdoi = {10.1016/j.aucc.2018.03.005},\n\tlanguage = {en},\n\tnumber = {2},\n\turldate = {2020-08-23},\n\tjournal = {Australian Critical Care},\n\tauthor = {Mackle, Diane and Nelson, Katherine},\n\tmonth = mar,\n\tyear = {2019},\n\tnote = {Number: 2},\n\tpages = {148--154},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Development and Validation of a Score to Identify Cardiac Surgery Patients at High Risk of Prolonged Mechanical Ventilation.\n \n \n \n \n\n\n \n Hessels, L.; Coulson, T. G.; Seevanayagam, S.; Young, P.; Pilcher, D.; Marhoon, N.; and Bellomo, R.\n\n\n \n\n\n\n Journal of Cardiothoracic and Vascular Anesthesia, 33(10): 2709–2716. October 2019.\n Number: 10\n\n\n\n
\n\n\n\n \n \n \"DevelopmentPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{hessels_development_2019,\n\ttitle = {Development and {Validation} of a {Score} to {Identify} {Cardiac} {Surgery} {Patients} at {High} {Risk} of {Prolonged} {Mechanical} {Ventilation}},\n\tvolume = {33},\n\tissn = {10530770},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S1053077019302691},\n\tdoi = {10.1053/j.jvca.2019.03.009},\n\tlanguage = {en},\n\tnumber = {10},\n\turldate = {2020-08-23},\n\tjournal = {Journal of Cardiothoracic and Vascular Anesthesia},\n\tauthor = {Hessels, Lara and Coulson, Tim G. and Seevanayagam, Siven and Young, Paul and Pilcher, David and Marhoon, Nada and Bellomo, Rinaldo},\n\tmonth = oct,\n\tyear = {2019},\n\tnote = {Number: 10},\n\tpages = {2709--2716},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Why do multicenter randomized controlled trials not confirm the positive findings of single center randomized controlled trials in acute care?.\n \n \n \n \n\n\n \n Landoni, G.; Pieri, M.; Young, P. J.; and Bellomo, R.\n\n\n \n\n\n\n Minerva Anestesiologica, 85(2). February 2019.\n Number: 2\n\n\n\n
\n\n\n\n \n \n \"WhyPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{landoni_why_2019,\n\ttitle = {Why do multicenter randomized controlled trials not confirm the positive findings of single center randomized controlled trials in acute care?},\n\tvolume = {85},\n\tissn = {03759393, 18271596},\n\turl = {https://www.minervamedica.it/index2.php?show=R02Y2019N02A0194},\n\tdoi = {10.23736/S0375-9393.18.13070-7},\n\tnumber = {2},\n\turldate = {2020-08-23},\n\tjournal = {Minerva Anestesiologica},\n\tauthor = {Landoni, Giovanni and Pieri, Marina and Young, Paul J. and Bellomo, Rinaldo},\n\tmonth = feb,\n\tyear = {2019},\n\tnote = {Number: 2},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Vitamin C, Hydrocortisone and Thiamine in Patients with Septic Shock (VITAMINS) trial: study protocol and statistical analysis plan.\n \n \n \n\n\n \n Fujii, T.; Udy, A. A.; Deane, A. M.; Luethi, N.; Bailey, M.; Eastwood, G. M.; Frei, D.; French, C.; Orford, N.; Shehabi, Y.; Young, P. J.; Bellomo, R.; and VITAMINS trial investigators\n\n\n \n\n\n\n Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 21(2): 119–125. June 2019.\n Number: 2\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{fujii_vitamin_2019,\n\ttitle = {Vitamin {C}, {Hydrocortisone} and {Thiamine} in {Patients} with {Septic} {Shock} ({VITAMINS}) trial: study protocol and statistical analysis plan},\n\tvolume = {21},\n\tissn = {1441-2772},\n\tshorttitle = {Vitamin {C}, {Hydrocortisone} and {Thiamine} in {Patients} with {Septic} {Shock} ({VITAMINS}) trial},\n\tabstract = {BACKGROUND: Septic shock is associated with poor outcomes. Vitamin C (ascorbic acid) is a cellular antioxidant and has anti-inflammatory properties. Whether the combination therapy of vitamin C, thiamine and hydrocortisone reduces vasopressor dependency in septic shock is unclear.\nOBJECTIVES: To describe the protocol and statistical analysis plan of a multicentre, open-label, prospective, phase 2 randomised clinical trial evaluating the effects of vitamin C, thiamine and hydrocortisone when compared with hydrocortisone monotherapy on the duration of vasopressor administration in critically ill patients with septic shock.\nMETHODS: VITAMINS is a multicentre cardiovascular efficacy trial in adult patients with septic shock. Randomisation occurs via a secure website with stratification by site, and allocation concealment is maintained throughout the trial. The primary outcome is the duration of time alive and free of vasopressor administration at Day 7. Secondary outcomes include feasibility endpoints and some patientcentred outcomes. All analyses will be conducted on an intention-to-treat basis.\nCONCLUSION: The VITAMINS trial will determine whether combination therapy of vitamin C, thiamine and hydrocortisone when compared with hydrocortisone increases vasopressor-free hours in critically ill patients with septic shock. The conduct of this study will provide important information on the feasibility of studying this intervention in a phase 3 trial.\nTRIAL REGISTRATION: ClinicalTrials.gov, identification No. NCT03333278.},\n\tlanguage = {eng},\n\tnumber = {2},\n\tjournal = {Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine},\n\tauthor = {Fujii, Tomoko and Udy, Andrew A. and Deane, Adam M. and Luethi, Nora and Bailey, Michael and Eastwood, Glenn M. and Frei, Daniel and French, Craig and Orford, Neil and Shehabi, Yahya and Young, Paul J. and Bellomo, Rinaldo and {VITAMINS trial investigators}},\n\tmonth = jun,\n\tyear = {2019},\n\tpmid = {31142242},\n\tnote = {Number: 2},\n\tkeywords = {Adult, Ascorbic Acid, Drug Therapy, Combination, Female, Hospital Mortality, Humans, Hydrocortisone, Intensive Care Units, Male, Prospective Studies, Shock, Septic, Thiamine, Treatment Outcome, Vasoconstrictor Agents, Vitamins},\n\tpages = {119--125},\n}\n\n
\n
\n\n\n
\n BACKGROUND: Septic shock is associated with poor outcomes. Vitamin C (ascorbic acid) is a cellular antioxidant and has anti-inflammatory properties. Whether the combination therapy of vitamin C, thiamine and hydrocortisone reduces vasopressor dependency in septic shock is unclear. OBJECTIVES: To describe the protocol and statistical analysis plan of a multicentre, open-label, prospective, phase 2 randomised clinical trial evaluating the effects of vitamin C, thiamine and hydrocortisone when compared with hydrocortisone monotherapy on the duration of vasopressor administration in critically ill patients with septic shock. METHODS: VITAMINS is a multicentre cardiovascular efficacy trial in adult patients with septic shock. Randomisation occurs via a secure website with stratification by site, and allocation concealment is maintained throughout the trial. The primary outcome is the duration of time alive and free of vasopressor administration at Day 7. Secondary outcomes include feasibility endpoints and some patientcentred outcomes. All analyses will be conducted on an intention-to-treat basis. CONCLUSION: The VITAMINS trial will determine whether combination therapy of vitamin C, thiamine and hydrocortisone when compared with hydrocortisone increases vasopressor-free hours in critically ill patients with septic shock. The conduct of this study will provide important information on the feasibility of studying this intervention in a phase 3 trial. TRIAL REGISTRATION: ClinicalTrials.gov, identification No. NCT03333278.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Targeted hypothermia versus targeted Normothermia after out-of-hospital cardiac arrest (TTM2): A randomized clinical trial—Rationale and design.\n \n \n \n \n\n\n \n Dankiewicz, J.; Cronberg, T.; Lilja, G.; Jakobsen, J. C.; Bělohlávek, J.; Callaway, C.; Cariou, A.; Eastwood, G.; Erlinge, D.; Hovdenes, J.; Joannidis, M.; Kirkegaard, H.; Kuiper, M.; Levin, H.; Morgan, M. P.; Nichol, A. D; Nordberg, P.; Oddo, M.; Pelosi, P.; Rylander, C.; Saxena, M.; Storm, C.; Taccone, F.; Ullén, S.; Wise, M. P.; Young, P.; Friberg, H.; and Nielsen, N.\n\n\n \n\n\n\n American Heart Journal, 217: 23–31. November 2019.\n \n\n\n\n
\n\n\n\n \n \n \"TargetedPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{dankiewicz_targeted_2019,\n\ttitle = {Targeted hypothermia versus targeted {Normothermia} after out-of-hospital cardiac arrest ({TTM2}): {A} randomized clinical trial—{Rationale} and design},\n\tvolume = {217},\n\tissn = {00028703},\n\tshorttitle = {Targeted hypothermia versus targeted {Normothermia} after out-of-hospital cardiac arrest ({TTM2})},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S0002870319301577},\n\tdoi = {10.1016/j.ahj.2019.06.012},\n\tlanguage = {en},\n\turldate = {2020-08-23},\n\tjournal = {American Heart Journal},\n\tauthor = {Dankiewicz, Josef and Cronberg, Tobias and Lilja, Gisela and Jakobsen, Janus Christian and Bělohlávek, Jan and Callaway, Clifton and Cariou, Alain and Eastwood, Glenn and Erlinge, David and Hovdenes, Jan and Joannidis, Michael and Kirkegaard, Hans and Kuiper, Michael and Levin, Helena and Morgan, Matt P.G. and Nichol, Alistair D and Nordberg, Per and Oddo, Mauro and Pelosi, Paolo and Rylander, Christian and Saxena, Manoj and Storm, Christian and Taccone, Fabio and Ullén, Susann and Wise, Matthew P. and Young, Paul and Friberg, Hans and Nielsen, Niklas},\n\tmonth = nov,\n\tyear = {2019},\n\tpages = {23--31},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Study protocol: A randomized controlled trial assessing the avoidance of endotracheal suction in cardiac surgical patients ventilated for ≤ 12 hr.\n \n \n \n \n\n\n \n Gilder, E.; Parke, R. L.; McGuinness, S.; and Jull, A.\n\n\n \n\n\n\n Journal of Advanced Nursing, 75(9): 2006–2014. September 2019.\n Number: 9\n\n\n\n
\n\n\n\n \n \n \"StudyPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{gilder_study_2019,\n\ttitle = {Study protocol: {A} randomized controlled trial assessing the avoidance of endotracheal suction in cardiac surgical patients ventilated for ≤ 12 hr},\n\tvolume = {75},\n\tissn = {0309-2402, 1365-2648},\n\tshorttitle = {Study protocol},\n\turl = {https://onlinelibrary.wiley.com/doi/abs/10.1111/jan.13994},\n\tdoi = {10.1111/jan.13994},\n\tlanguage = {en},\n\tnumber = {9},\n\turldate = {2020-08-23},\n\tjournal = {Journal of Advanced Nursing},\n\tauthor = {Gilder, Eileen and Parke, Rachael L. and McGuinness, Shay and Jull, Andrew},\n\tmonth = sep,\n\tyear = {2019},\n\tnote = {Number: 9},\n\tpages = {2006--2014},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Vitamin C therapy for patients with sepsis or septic shock: a protocol for a systematic review and a network meta-analysis.\n \n \n \n\n\n \n Fujii, T.; Belletti, A.; Carr, A.; Furukawa, T. A.; Luethi, N.; Putzu, A.; Sartini, C.; Salanti, G.; Tsujimoto, Y.; Udy, A. A.; Young, P. J.; and Bellomo, R.\n\n\n \n\n\n\n BMJ open, 9(11): e033458. 2019.\n Number: 11\n\n\n\n
\n\n\n\n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{fujii_vitamin_2019-1,\n\ttitle = {Vitamin {C} therapy for patients with sepsis or septic shock: a protocol for a systematic review and a network meta-analysis},\n\tvolume = {9},\n\tissn = {2044-6055},\n\tshorttitle = {Vitamin {C} therapy for patients with sepsis or septic shock},\n\tdoi = {10.1136/bmjopen-2019-033458},\n\tabstract = {INTRODUCTION: Vasoplegia is common and associated with a poor prognosis in patients with sepsis and septic shock. Vitamin C therapy in combination with vitamin B1 and glucocorticoid, as well as monotherapy in various doses, has been investigated as a treatment for the vasoplegic state in sepsis, through targeting the inflammatory cascade. However, the combination effect and the relative contribution of each drug have not been well evaluated. Furthermore, the best combination between the three agents is currently unknown. We are planning a systematic review (SR) with network meta-analysis (NMA) to compare the different treatments and identify the combination with the most favourable effect on survival.\nMETHODS AND ANALYSIS: We will include all randomised controlled trials comparing any intervention using intravenous vitamin C, vitamin B1 and/or glucocorticoid with another or with placebo in the treatment of sepsis. We are interested in comparing the following active interventions. Very high-dose vitamin C (≥12 g/day), high-dose vitamin C (≥6 g/day), vitamin C ({\\textless}6 g/day); low-dose glucocorticoid ({\\textless}400 mg/day of hydrocortisone (or equivalent)), vitamin B1 and combinations of the drugs above. The primary outcome will be all-cause mortality at the longest follow-up within 1 year but 90 days or longer postrandomisation. All relevant studies will be sought through database searches and trial registries. All reference selection and data extraction will be conducted by two independent reviewers. We will conduct a random-effects NMA to synthesise all evidence for each outcome and obtain a comprehensive ranking of all treatments. We will use the surface under the cumulative ranking curve and the mean ranks to rank the various interventions. To differentiate between the effect of combination therapies and the effect of a component, we will employ a component NMA.\nETHICS AND DISSEMINATION: This SR does not require ethical approval. We will publish findings from this systematic review in a peer-reviewed scientific journal and present these at scientific conferences.\nPROSPERO REGISTRATION NUMBER: CRD42018103860.},\n\tlanguage = {eng},\n\tnumber = {11},\n\tjournal = {BMJ open},\n\tauthor = {Fujii, Tomoko and Belletti, Alessandro and Carr, Anitra and Furukawa, Toshi A. and Luethi, Nora and Putzu, Alessandro and Sartini, Chiara and Salanti, Georgia and Tsujimoto, Yasushi and Udy, Andrew A. and Young, Paul J. and Bellomo, Rinaldo},\n\tyear = {2019},\n\tpmid = {31722954},\n\tpmcid = {PMC6858173},\n\tnote = {Number: 11},\n\tkeywords = {adult intensive \\& critical care, clinical trials, statistics \\& research methods},\n\tpages = {e033458},\n}\n\n
\n
\n\n\n
\n INTRODUCTION: Vasoplegia is common and associated with a poor prognosis in patients with sepsis and septic shock. Vitamin C therapy in combination with vitamin B1 and glucocorticoid, as well as monotherapy in various doses, has been investigated as a treatment for the vasoplegic state in sepsis, through targeting the inflammatory cascade. However, the combination effect and the relative contribution of each drug have not been well evaluated. Furthermore, the best combination between the three agents is currently unknown. We are planning a systematic review (SR) with network meta-analysis (NMA) to compare the different treatments and identify the combination with the most favourable effect on survival. METHODS AND ANALYSIS: We will include all randomised controlled trials comparing any intervention using intravenous vitamin C, vitamin B1 and/or glucocorticoid with another or with placebo in the treatment of sepsis. We are interested in comparing the following active interventions. Very high-dose vitamin C (≥12 g/day), high-dose vitamin C (≥6 g/day), vitamin C (\\textless6 g/day); low-dose glucocorticoid (\\textless400 mg/day of hydrocortisone (or equivalent)), vitamin B1 and combinations of the drugs above. The primary outcome will be all-cause mortality at the longest follow-up within 1 year but 90 days or longer postrandomisation. All relevant studies will be sought through database searches and trial registries. All reference selection and data extraction will be conducted by two independent reviewers. We will conduct a random-effects NMA to synthesise all evidence for each outcome and obtain a comprehensive ranking of all treatments. We will use the surface under the cumulative ranking curve and the mean ranks to rank the various interventions. To differentiate between the effect of combination therapies and the effect of a component, we will employ a component NMA. ETHICS AND DISSEMINATION: This SR does not require ethical approval. We will publish findings from this systematic review in a peer-reviewed scientific journal and present these at scientific conferences. PROSPERO REGISTRATION NUMBER: CRD42018103860.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Practice patterns and perceptions of Australian and New Zealand anaesthetists towards perioperative oxygen therapy.\n \n \n \n \n\n\n \n Frei, D. R; Beasley, R.; Campbell, D.; Leslie, K.; Merry, A. F; Moore, M.; Myles, P. S; Ruawai-Hamilton, L.; Short, T. G; and Young, P. J\n\n\n \n\n\n\n Anaesthesia and Intensive Care, 47(3): 288–294. May 2019.\n Number: 3\n\n\n\n
\n\n\n\n \n \n \"PracticePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{frei_practice_2019,\n\ttitle = {Practice patterns and perceptions of {Australian} and {New} {Zealand} anaesthetists towards perioperative oxygen therapy},\n\tvolume = {47},\n\tissn = {0310-057X, 1448-0271},\n\turl = {http://journals.sagepub.com/doi/10.1177/0310057X19842245},\n\tdoi = {10.1177/0310057X19842245},\n\tabstract = {We conducted a survey of Australian and New Zealand anaesthetists to determine self-reported practice of perioperative oxygen administration and to quantify perceptions regarding the perceived benefits and risks resulting from liberal oxygen therapy delivered in a manner consistent with the current World Health Organization guidelines. In addition, we sought feedback on the acceptability of several proposed clinical trial designs aiming to assess the overall effect of liberal and restricted perioperative oxygen regimens on patient outcomes. We developed a 23-question electronic survey that was emailed to 972 randomly selected Australian and New Zealand College of Anaesthetists (ANZCA) Fellows. We received responses from 282 of 972 invitees (response rate 29\\%). The majority of survey participants indicated that they routinely titrate inspired oxygen to a level they feel is safe (164/282, 58\\%) or minimise oxygen administration (82/282, 29\\%), while 5\\% of respondents indicated that they aim to maximise oxygen administration. The mean value for targeted intraoperative fraction inspired oxygen (FiO\n              2\n              ) was 0.41 (standard deviation 0.12). Of the survey respondents, 2/282 (0.7\\%) indicated they believe that routine intra- and postoperative administration of ≥80\\% oxygen reduces the risk of surgical site infection. Well-designed and conducted randomised trials on this topic may help to better direct clinicians' choices. A high level of willingness to participate (80\\% of responses) in a study designed to investigate the impact of differing approaches to perioperative oxygen administration suggests that recruitment is likely to be feasible in a future study.},\n\tlanguage = {en},\n\tnumber = {3},\n\turldate = {2020-08-23},\n\tjournal = {Anaesthesia and Intensive Care},\n\tauthor = {Frei, Daniel R and Beasley, Richard and Campbell, Douglas and Leslie, Kate and Merry, Alan F and Moore, Matthew and Myles, Paul S and Ruawai-Hamilton, Laura and Short, Tim G and Young, Paul J},\n\tmonth = may,\n\tyear = {2019},\n\tnote = {Number: 3},\n\tpages = {288--294},\n}\n\n
\n
\n\n\n
\n We conducted a survey of Australian and New Zealand anaesthetists to determine self-reported practice of perioperative oxygen administration and to quantify perceptions regarding the perceived benefits and risks resulting from liberal oxygen therapy delivered in a manner consistent with the current World Health Organization guidelines. In addition, we sought feedback on the acceptability of several proposed clinical trial designs aiming to assess the overall effect of liberal and restricted perioperative oxygen regimens on patient outcomes. We developed a 23-question electronic survey that was emailed to 972 randomly selected Australian and New Zealand College of Anaesthetists (ANZCA) Fellows. We received responses from 282 of 972 invitees (response rate 29%). The majority of survey participants indicated that they routinely titrate inspired oxygen to a level they feel is safe (164/282, 58%) or minimise oxygen administration (82/282, 29%), while 5% of respondents indicated that they aim to maximise oxygen administration. The mean value for targeted intraoperative fraction inspired oxygen (FiO 2 ) was 0.41 (standard deviation 0.12). Of the survey respondents, 2/282 (0.7%) indicated they believe that routine intra- and postoperative administration of ≥80% oxygen reduces the risk of surgical site infection. Well-designed and conducted randomised trials on this topic may help to better direct clinicians' choices. A high level of willingness to participate (80% of responses) in a study designed to investigate the impact of differing approaches to perioperative oxygen administration suggests that recruitment is likely to be feasible in a future study.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Increased risk of mortality with liberal oxygen therapy compared with conservative oxygen therapy in critically ill adults.\n \n \n \n \n\n\n \n Beasley, R.; and Mackle, D.\n\n\n \n\n\n\n BMJ Evidence-Based Medicine, 24(3): 113–114. June 2019.\n Number: 3\n\n\n\n
\n\n\n\n \n \n \"IncreasedPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{beasley_increased_2019,\n\ttitle = {Increased risk of mortality with liberal oxygen therapy compared with conservative oxygen therapy in critically ill adults},\n\tvolume = {24},\n\tissn = {2515-446X, 2515-4478},\n\turl = {http://ebm.bmj.com/lookup/doi/10.1136/bmjebm-2018-111054},\n\tdoi = {10.1136/bmjebm-2018-111054},\n\tlanguage = {en},\n\tnumber = {3},\n\turldate = {2020-08-23},\n\tjournal = {BMJ Evidence-Based Medicine},\n\tauthor = {Beasley, Richard and Mackle, Diane},\n\tmonth = jun,\n\tyear = {2019},\n\tnote = {Number: 3},\n\tpages = {113--114},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2018\n \n \n (1)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n Protocol summary and statistical analysis plan for the intensive care unit randomised trial comparing two approaches to oxygen therapy (ICU-ROX).\n \n \n \n\n\n \n Mackle, D. M; Bailey, M. J; Beasley, R. W; Bellomo, R.; Bennett, V.; Deane, A.; Eastwood, G. M; Finfer, S.; Freebairn, R.; and Litton, E.\n\n\n \n\n\n\n Critical Care and Resuscitation, 20(1): 22. 2018.\n Number: 1 Publisher: The Australasian Medical Publishing Company\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{mackle_protocol_2018,\n\ttitle = {Protocol summary and statistical analysis plan for the intensive care unit randomised trial comparing two approaches to oxygen therapy ({ICU}-{ROX})},\n\tvolume = {20},\n\tnumber = {1},\n\tjournal = {Critical Care and Resuscitation},\n\tauthor = {Mackle, Diane M and Bailey, Michael J and Beasley, Richard W and Bellomo, Rinaldo and Bennett, Victoria and Deane, Adam and Eastwood, Glenn M and Finfer, Simon and Freebairn, Ross and Litton, Edward},\n\tyear = {2018},\n\tnote = {Number: 1\nPublisher: The Australasian Medical Publishing Company},\n\tpages = {22},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2017\n \n \n (6)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n Protocol and statistical analysis plan for the Randomised Evaluation of Active Control of Temperature versus Ordinary Temperature Management (REACTOR) trial.\n \n \n \n\n\n \n Young, P. J.; Bailey, M. J.; Beasley, R. W.; Freebairn, R. C.; Hammond, N. E.; Haren, F. M. P. v.; Harward, M. L.; Henderson, S. J.; Mackle, D. M.; McArthur, C. J.; McGuinness, S. P.; Myburgh, J. A.; Saxena, M. K.; Turner, A.; Webb, S. A. R.; Bellomo, R.; and The ANZICS Clinical Trials Group\n\n\n \n\n\n\n Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 19(1): 81–87. March 2017.\n Number: 1\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{young_protocol_2017,\n\ttitle = {Protocol and statistical analysis plan for the {Randomised} {Evaluation} of {Active} {Control} of {Temperature} versus {Ordinary} {Temperature} {Management} ({REACTOR}) trial},\n\tvolume = {19},\n\tissn = {1441-2772},\n\tabstract = {BACKGROUND: Body temperature can be reduced in febrile patients in the intensive care unit using medicines and physical cooling devices, but it is not known whether systematically preventing and treating fever reduces body temperature compared with standard care.\nOBJECTIVE: To describe the study protocol and statistical analysis plan for the Randomised Evaluation of Active Control of Temperature versus Ordinary Temperature Management (REACTOR) trial.\nDESIGN, SETTING AND PARTICIPANTS: Protocol for a phase II, multicentre trial to be conducted in Australian and New Zealand ICUs admitting adult patients. We will recruit 184 adults without acute brain injury who are expected to be ventilated in the ICU beyond the day after randomisation. We will use open, random, parallel assignment to systematic prevention and treatment of fever, or to standard temperature management.\nMAIN OUTCOME MEASURES: The primary end point will be mean body temperature, calculated from body temperatures measured 6-hourly for 7 days (168 hours) or until ICU discharge, whichever is sooner. Secondary end points are ICU-free days, in-hospital and cause-specific mortality (censored at Day 90) and survival time to Day 90 (censored at hospital discharge).\nRESULTS AND CONCLUSIONS: The trial will determine whether active temperature control reduces body temperature compared with standard care. It is primarily being conducted to establish whether a phase III trial with a patient-centred end point of Day 90 mortality is justified and feasible.},\n\tlanguage = {eng},\n\tnumber = {1},\n\tjournal = {Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine},\n\tauthor = {Young, Paul J. and Bailey, Michael J. and Beasley, Richard W. and Freebairn, Ross C. and Hammond, Naomi E. and Haren, Frank M. P. van and Harward, Meg L. and Henderson, Seton J. and Mackle, Diane M. and McArthur, Colin J. and McGuinness, Shay P. and Myburgh, John A. and Saxena, Manoj K. and Turner, Anne and Webb, Steve A. R. and Bellomo, Rinaldo and {The ANZICS Clinical Trials Group}},\n\tmonth = mar,\n\tyear = {2017},\n\tpmid = {28215136},\n\tnote = {Number: 1},\n\tkeywords = {Clinical Protocols, Fever, Humans, Intensive Care Units, Research Design},\n\tpages = {81--87},\n}\n\n
\n
\n\n\n
\n BACKGROUND: Body temperature can be reduced in febrile patients in the intensive care unit using medicines and physical cooling devices, but it is not known whether systematically preventing and treating fever reduces body temperature compared with standard care. OBJECTIVE: To describe the study protocol and statistical analysis plan for the Randomised Evaluation of Active Control of Temperature versus Ordinary Temperature Management (REACTOR) trial. DESIGN, SETTING AND PARTICIPANTS: Protocol for a phase II, multicentre trial to be conducted in Australian and New Zealand ICUs admitting adult patients. We will recruit 184 adults without acute brain injury who are expected to be ventilated in the ICU beyond the day after randomisation. We will use open, random, parallel assignment to systematic prevention and treatment of fever, or to standard temperature management. MAIN OUTCOME MEASURES: The primary end point will be mean body temperature, calculated from body temperatures measured 6-hourly for 7 days (168 hours) or until ICU discharge, whichever is sooner. Secondary end points are ICU-free days, in-hospital and cause-specific mortality (censored at Day 90) and survival time to Day 90 (censored at hospital discharge). RESULTS AND CONCLUSIONS: The trial will determine whether active temperature control reduces body temperature compared with standard care. It is primarily being conducted to establish whether a phase III trial with a patient-centred end point of Day 90 mortality is justified and feasible.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n The Plasma-Lyte 148 v Saline (PLUS) study protocol: a multicentre, randomised controlled trial of the effect of intensive care fluid therapy on mortality.\n \n \n \n\n\n \n Hammond, N. E.; Bellomo, R.; Gallagher, M.; Gattas, D.; Glass, P.; Mackle, D.; Micallef, S.; Myburgh, J.; Saxena, M.; Taylor, C.; Young, P.; and Finfer, S.\n\n\n \n\n\n\n Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 19(3): 239–246. September 2017.\n Number: 3\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{hammond_plasma-lyte_2017,\n\ttitle = {The {Plasma}-{Lyte} 148 v {Saline} ({PLUS}) study protocol: a multicentre, randomised controlled trial of the effect of intensive care fluid therapy on mortality},\n\tvolume = {19},\n\tissn = {1441-2772},\n\tshorttitle = {The {Plasma}-{Lyte} 148 v {Saline} ({PLUS}) study protocol},\n\tabstract = {BACKGROUND: 0.9\\% sodium chloride (saline) is the most commonly administered resuscitation fluid on a global basis but emerging evidence suggests that its high chloride content may have important adverse effects.\nOBJECTIVE: To describe the study protocol for the Plasma- Lyte 148 v Saline study, which will test the hypothesis that in critically ill adult patients the use of Plasma-Lyte 148 (a buffered crystalloid solution) for fluid therapy results in different 90-day all-cause mortality when compared with saline.\nDESIGN AND SETTING: We will conduct this multicentre, blinded, randomised controlled trial in approximately 50 intensive care units in Australia and New Zealand. We will randomly assign 8800 patients to either Plasma-Lyte 148 or saline for all resuscitation fluid, maintenance fluid and compatible drug dilution therapy while in the ICU for up to 90 days after randomisation.\nOUTCOME MEASURES: The primary outcome is 90-day all-cause mortality; secondary outcomes include mean and peak creatinine concentration, incidence of renal replacement therapy, incidence and duration of vasoactive drug treatment, duration of mechanical ventilation, ICU and hospital length of stay, and quality of life and health services use at 6 months.\nRESULTS AND CONCLUSIONS: The PLUS study will provide high-quality data on the comparative safety and efficacy of Plasma-Lyte 148 compared with saline for resuscitation and compatible crystalloid fluid therapy in critically ill adult patients.},\n\tlanguage = {eng},\n\tnumber = {3},\n\tjournal = {Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine},\n\tauthor = {Hammond, Naomi E. and Bellomo, Rinaldo and Gallagher, Martin and Gattas, David and Glass, Parisa and Mackle, Diane and Micallef, Sharon and Myburgh, John and Saxena, Manoj and Taylor, Colman and Young, Paul and Finfer, Simon},\n\tmonth = sep,\n\tyear = {2017},\n\tpmid = {28866974},\n\tnote = {Number: 3},\n\tkeywords = {Australia, Creatinine, Critical Illness, Fluid Therapy, Gluconates, Health Services, Humans, Intensive Care Units, Length of Stay, Magnesium Chloride, Mortality, New Zealand, Potassium Chloride, Quality of Life, Renal Replacement Therapy, Respiration, Artificial, Resuscitation, Sodium Acetate, Sodium Chloride, Time Factors, Vasoconstrictor Agents, Vasodilator Agents},\n\tpages = {239--246},\n}\n\n
\n
\n\n\n
\n BACKGROUND: 0.9% sodium chloride (saline) is the most commonly administered resuscitation fluid on a global basis but emerging evidence suggests that its high chloride content may have important adverse effects. OBJECTIVE: To describe the study protocol for the Plasma- Lyte 148 v Saline study, which will test the hypothesis that in critically ill adult patients the use of Plasma-Lyte 148 (a buffered crystalloid solution) for fluid therapy results in different 90-day all-cause mortality when compared with saline. DESIGN AND SETTING: We will conduct this multicentre, blinded, randomised controlled trial in approximately 50 intensive care units in Australia and New Zealand. We will randomly assign 8800 patients to either Plasma-Lyte 148 or saline for all resuscitation fluid, maintenance fluid and compatible drug dilution therapy while in the ICU for up to 90 days after randomisation. OUTCOME MEASURES: The primary outcome is 90-day all-cause mortality; secondary outcomes include mean and peak creatinine concentration, incidence of renal replacement therapy, incidence and duration of vasoactive drug treatment, duration of mechanical ventilation, ICU and hospital length of stay, and quality of life and health services use at 6 months. RESULTS AND CONCLUSIONS: The PLUS study will provide high-quality data on the comparative safety and efficacy of Plasma-Lyte 148 compared with saline for resuscitation and compatible crystalloid fluid therapy in critically ill adult patients.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Age of Red Cells for Transfusion and Outcomes in Critically Ill Adults.\n \n \n \n \n\n\n \n Cooper, D. J.; McQuilten, Z. K.; Nichol, A.; Ady, B.; Aubron, C.; Bailey, M.; Bellomo, R.; Gantner, D.; Irving, D. O.; Kaukonen, K.; McArthur, C.; Murray, L.; Pettilä, V.; and French, C.\n\n\n \n\n\n\n New England Journal of Medicine, 377(19): 1858–1867. November 2017.\n Number: 19\n\n\n\n
\n\n\n\n \n \n \"AgePaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{cooper_age_2017,\n\ttitle = {Age of {Red} {Cells} for {Transfusion} and {Outcomes} in {Critically} {Ill} {Adults}},\n\tvolume = {377},\n\tissn = {0028-4793, 1533-4406},\n\turl = {http://www.nejm.org/doi/10.1056/NEJMoa1707572},\n\tdoi = {10.1056/NEJMoa1707572},\n\tlanguage = {en},\n\tnumber = {19},\n\turldate = {2020-08-23},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {Cooper, D. James and McQuilten, Zoe K. and Nichol, Alistair and Ady, Bridget and Aubron, Cécile and Bailey, Michael and Bellomo, Rinaldo and Gantner, Dashiell and Irving, David O. and Kaukonen, Kirsi-Maija and McArthur, Colin and Murray, Lynne and Pettilä, Ville and French, Craig},\n\tmonth = nov,\n\tyear = {2017},\n\tnote = {Number: 19},\n\tpages = {1858--1867},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Angiotensin II for the Treatment of Vasodilatory Shock.\n \n \n \n \n\n\n \n Khanna, A.; English, S. W.; Wang, X. S.; Ham, K.; Tumlin, J.; Szerlip, H.; Busse, L. W.; Altaweel, L.; Albertson, T. E.; Mackey, C.; McCurdy, M. T.; Boldt, D. W.; Chock, S.; Young, P. J.; Krell, K.; Wunderink, R. G.; Ostermann, M.; Murugan, R.; Gong, M. N.; Panwar, R.; Hästbacka, J.; Favory, R.; Venkatesh, B.; Thompson, B. T.; Bellomo, R.; Jensen, J.; Kroll, S.; Chawla, L. S.; Tidmarsh, G. F.; and Deane, A. M.\n\n\n \n\n\n\n New England Journal of Medicine, 377(5): 419–430. August 2017.\n Number: 5\n\n\n\n
\n\n\n\n \n \n \"AngiotensinPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{khanna_angiotensin_2017,\n\ttitle = {Angiotensin {II} for the {Treatment} of {Vasodilatory} {Shock}},\n\tvolume = {377},\n\tissn = {0028-4793, 1533-4406},\n\turl = {http://www.nejm.org/doi/10.1056/NEJMoa1704154},\n\tdoi = {10.1056/NEJMoa1704154},\n\tlanguage = {en},\n\tnumber = {5},\n\turldate = {2020-08-23},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {Khanna, Ashish and English, Shane W. and Wang, Xueyuan S. and Ham, Kealy and Tumlin, James and Szerlip, Harold and Busse, Laurence W. and Altaweel, Laith and Albertson, Timothy E. and Mackey, Caleb and McCurdy, Michael T. and Boldt, David W. and Chock, Stefan and Young, Paul J. and Krell, Kenneth and Wunderink, Richard G. and Ostermann, Marlies and Murugan, Raghavan and Gong, Michelle N. and Panwar, Rakshit and Hästbacka, Johanna and Favory, Raphael and Venkatesh, Balasubramanian and Thompson, B. Taylor and Bellomo, Rinaldo and Jensen, Jeffrey and Kroll, Stew and Chawla, Lakhmir S. and Tidmarsh, George F. and Deane, Adam M.},\n\tmonth = aug,\n\tyear = {2017},\n\tnote = {Number: 5},\n\tpages = {419--430},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Intensive care unit randomised trial comparing two approaches to oxygen therapy (ICU-ROX): results of the pilot phase.\n \n \n \n\n\n \n Young, P. J; Mackle, D. M; Bailey, M. J; Beasley, R. W; Bennett, V. L; Deane, A. M; Eastwood, G. M; Finfer, S.; Freebairn, R. C; and Litton, E.\n\n\n \n\n\n\n Critical care and resuscitation: journal of the Australasian Academy of Critical Care Medicine, 19(4): 344–354. 2017.\n Number: 4 Publisher: Australasian Medical Publishing Co. Ltd\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{young_intensive_2017,\n\ttitle = {Intensive care unit randomised trial comparing two approaches to oxygen therapy ({ICU}-{ROX}): results of the pilot phase},\n\tvolume = {19},\n\tissn = {1441-2772},\n\tnumber = {4},\n\tjournal = {Critical care and resuscitation: journal of the Australasian Academy of Critical Care Medicine},\n\tauthor = {Young, Paul J and Mackle, Diane M and Bailey, Michael J and Beasley, Richard W and Bennett, Victoria L and Deane, Adam M and Eastwood, Glenn M and Finfer, Simon and Freebairn, Ross C and Litton, Edward},\n\tyear = {2017},\n\tnote = {Number: 4\nPublisher: Australasian Medical Publishing Co. Ltd},\n\tpages = {344--354},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Admitting elderly patients to icu: Is it just about survival?.\n \n \n \n\n\n \n Ritzema, J.; and Young, P.\n\n\n \n\n\n\n New Zealand Medical Journal, 130(1453): 9–10. 2017.\n Number: 1453\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{ritzema_admitting_2017,\n\ttitle = {Admitting elderly patients to icu: {Is} it just about survival?},\n\tvolume = {130},\n\tissn = {11758716},\n\tnumber = {1453},\n\tjournal = {New Zealand Medical Journal},\n\tauthor = {Ritzema, Jay and Young, Paul},\n\tyear = {2017},\n\tnote = {Number: 1453},\n\tpages = {9--10},\n}\n\n
\n
\n\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2016\n \n \n (4)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n The ICU mobility scale has construct and predictive validity and is responsive. A multicenter observational study.\n \n \n \n\n\n \n Tipping, C. J; Bailey, M. J; Bellomo, R.; Berney, S.; Buhr, H.; Denehy, L.; Harrold, M.; Holland, A.; Higgins, A. M; and Iwashyna, T. J\n\n\n \n\n\n\n Annals of the American Thoracic Society, 13(6): 887–893. 2016.\n Number: 6 Publisher: American Thoracic Society\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{tipping_icu_2016,\n\ttitle = {The {ICU} mobility scale has construct and predictive validity and is responsive. {A} multicenter observational study},\n\tvolume = {13},\n\tissn = {2329-6933},\n\tnumber = {6},\n\tjournal = {Annals of the American Thoracic Society},\n\tauthor = {Tipping, Claire J and Bailey, Michael J and Bellomo, Rinaldo and Berney, Susan and Buhr, Heidi and Denehy, Linda and Harrold, Meg and Holland, Anne and Higgins, Alisa M and Iwashyna, Theodore J},\n\tyear = {2016},\n\tnote = {Number: 6\nPublisher: American Thoracic Society},\n\tpages = {887--893},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n Acute Kidney Injury With Buffered Crystalloids vs Saline Among ICU Patients—Reply.\n \n \n \n\n\n \n Young, P.; Bailey, M.; and Bellomo, R.\n\n\n \n\n\n\n Jama, 315(14): 1521. 2016.\n Number: 14 Publisher: American Medical Association\n\n\n\n
\n\n\n\n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{young_acute_2016,\n\ttitle = {Acute {Kidney} {Injury} {With} {Buffered} {Crystalloids} vs {Saline} {Among} {ICU} {Patients}—{Reply}},\n\tvolume = {315},\n\tissn = {0098-7484},\n\tnumber = {14},\n\tjournal = {Jama},\n\tauthor = {Young, Paul and Bailey, Michael and Bellomo, Rinaldo},\n\tyear = {2016},\n\tnote = {Number: 14\nPublisher: American Medical Association},\n\tpages = {1521},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Acetaminophen to treat fever in intensive care unit patients with likely infection: a response from the author of the HEAT trial.\n \n \n \n \n\n\n \n Young, P.\n\n\n \n\n\n\n Journal of Thoracic Disease; Vol 8, No 7 (July 2016): Journal of Thoracic Disease. 2016.\n \n\n\n\n
\n\n\n\n \n \n \"AcetaminophenPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{young_acetaminophen_2016,\n\ttitle = {Acetaminophen to treat fever in intensive care unit patients with likely infection: a response from the author of the {HEAT} trial},\n\turl = {http://jtd.amegroups.com/article/view/7691},\n\tabstract = {The HEAT trial was a phase 2b randomized, double-blind, placebo-controlled trial designed to provide preliminary data on the safety and efficacy of using intravenous acetaminophen (paracetamol) to treat fever in intensive care unit (ICU) patients with likely infection (1,2). The trial and its interpretation in the wider context of existing literature on fever control were discussed in commentaries (3,4) and a perspective (5) published in recent issues.},\n\tjournal = {Journal of Thoracic Disease; Vol 8, No 7 (July 2016): Journal of Thoracic Disease},\n\tauthor = {Young, Paul},\n\tyear = {2016},\n}\n\n
\n
\n\n\n
\n The HEAT trial was a phase 2b randomized, double-blind, placebo-controlled trial designed to provide preliminary data on the safety and efficacy of using intravenous acetaminophen (paracetamol) to treat fever in intensive care unit (ICU) patients with likely infection (1,2). The trial and its interpretation in the wider context of existing literature on fever control were discussed in commentaries (3,4) and a perspective (5) published in recent issues.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n A Binational Multicenter Pilot Feasibility Randomized Controlled Trial of Early Goal-Directed Mobilization in the ICU*.\n \n \n \n \n\n\n \n Hodgson, C. L; Bailey, M.; Bellomo, R.; Berney, S.; Buhr, H.; Denehy, L.; Gabbe, B.; Harrold, M.; Higgins, A.; Iwashyna, T. J; Papworth, R.; Parke, R.; Patman, S.; Presneill, J.; Saxena, M.; Skinner, E.; Tipping, C.; Young, P.; and Webb, S.\n\n\n \n\n\n\n Critical Care Medicine, 44(6). 2016.\n Number: 6\n\n\n\n
\n\n\n\n \n \n \"APaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{hodgson_binational_2016,\n\ttitle = {A {Binational} {Multicenter} {Pilot} {Feasibility} {Randomized} {Controlled} {Trial} of {Early} {Goal}-{Directed} {Mobilization} in the {ICU}*},\n\tvolume = {44},\n\tissn = {0090-3493},\n\turl = {https://journals.lww.com/ccmjournal/Fulltext/2016/06000/A_Binational_Multicenter_Pilot_Feasibility.16.aspx},\n\tabstract = {Objectives: To determine if the early goal-directed mobilization intervention could be delivered to patients receiving mechanical ventilation with increased maximal levels of activity compared with standard care. Design: A pilot randomized controlled trial. Setting: Five ICUs in Australia and New Zealand. Participants: Fifty critically ill adults mechanically ventilated for greater than 24 hours. Intervention: Patients were randomly assigned to either early goal-directed mobilization (intervention) or to standard care (control). Early goal-directed mobilization comprised functional rehabilitation treatment conducted at the highest level of activity possible for that patient assessed by the ICU mobility scale while receiving mechanical ventilation. Measurements and Main Results: The ICU mobility scale, strength, ventilation duration, ICU and hospital length of stay, and total inpatient (acute and rehabilitation) stay as well as 6-month post-ICU discharge health-related quality of life, activities of daily living, and anxiety and depression were recorded. The mean age was 61 years and 60\\% were men. The highest level of activity (ICU mobility scale) recorded during the ICU stay between the intervention and control groups was mean (95\\% CI) 7.3 (6.3–8.3) versus 5.9 (4.9–6.9), p = 0.05. The proportion of patients who walked in ICU was almost doubled with early goal-directed mobilization (intervention n = 19 [66\\%] vs control n = 8 [38\\%]; p = 0.05). There was no difference in total inpatient stay (d) between the intervention versus control groups (20 [15–35] vs 34 [18–43]; p = 0.37). There were no adverse events. Conclusions: Key Practice Points: Delivery of early goal-directed mobilization within a randomized controlled trial was feasible, safe and resulted in increased duration and level of active exercises.},\n\tnumber = {6},\n\tjournal = {Critical Care Medicine},\n\tauthor = {Hodgson, Carol L and Bailey, Michael and Bellomo, Rinaldo and Berney, Susan and Buhr, Heidi and Denehy, Linda and Gabbe, Belinda and Harrold, Megan and Higgins, Alisa and Iwashyna, Theodore J and Papworth, Rebecca and Parke, Rachael and Patman, Shane and Presneill, Jeffrey and Saxena, Manoj and Skinner, Elizabeth and Tipping, Claire and Young, Paul and Webb, Steven},\n\tyear = {2016},\n\tnote = {Number: 6},\n\tkeywords = {early mobilization, intensive care, mechanical ventilation, physical therapy, randomized trial, rehabilitation},\n}\n
\n
\n\n\n
\n Objectives: To determine if the early goal-directed mobilization intervention could be delivered to patients receiving mechanical ventilation with increased maximal levels of activity compared with standard care. Design: A pilot randomized controlled trial. Setting: Five ICUs in Australia and New Zealand. Participants: Fifty critically ill adults mechanically ventilated for greater than 24 hours. Intervention: Patients were randomly assigned to either early goal-directed mobilization (intervention) or to standard care (control). Early goal-directed mobilization comprised functional rehabilitation treatment conducted at the highest level of activity possible for that patient assessed by the ICU mobility scale while receiving mechanical ventilation. Measurements and Main Results: The ICU mobility scale, strength, ventilation duration, ICU and hospital length of stay, and total inpatient (acute and rehabilitation) stay as well as 6-month post-ICU discharge health-related quality of life, activities of daily living, and anxiety and depression were recorded. The mean age was 61 years and 60% were men. The highest level of activity (ICU mobility scale) recorded during the ICU stay between the intervention and control groups was mean (95% CI) 7.3 (6.3–8.3) versus 5.9 (4.9–6.9), p = 0.05. The proportion of patients who walked in ICU was almost doubled with early goal-directed mobilization (intervention n = 19 [66%] vs control n = 8 [38%]; p = 0.05). There was no difference in total inpatient stay (d) between the intervention versus control groups (20 [15–35] vs 34 [18–43]; p = 0.37). There were no adverse events. Conclusions: Key Practice Points: Delivery of early goal-directed mobilization within a randomized controlled trial was feasible, safe and resulted in increased duration and level of active exercises.\n
\n\n\n
\n\n\n\n\n\n
\n
\n\n
\n
\n  \n 2015\n \n \n (8)\n \n \n
\n
\n \n \n
\n \n\n \n \n \n \n \n \n Erythropoietin in traumatic brain injury (EPO-TBI): a double-blind randomised controlled trial.\n \n \n \n \n\n\n \n Nichol, A.; French, C.; Little, L.; Haddad, S.; Presneill, J.; Arabi, Y.; Bailey, M.; Cooper, D J.; Duranteau, J.; Huet, O.; Mak, A.; McArthur, C.; Pettilä, V.; Skrifvars, M.; Vallance, S.; Varma, D.; Wills, J.; and Bellomo, R.\n\n\n \n\n\n\n The Lancet, 386(10012): 2499–2506. December 2015.\n Number: 10012\n\n\n\n
\n\n\n\n \n \n \"ErythropoietinPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{nichol_erythropoietin_2015,\n\ttitle = {Erythropoietin in traumatic brain injury ({EPO}-{TBI}): a double-blind randomised controlled trial},\n\tvolume = {386},\n\tissn = {01406736},\n\tshorttitle = {Erythropoietin in traumatic brain injury ({EPO}-{TBI})},\n\turl = {https://linkinghub.elsevier.com/retrieve/pii/S0140673615003864},\n\tdoi = {10.1016/S0140-6736(15)00386-4},\n\tlanguage = {en},\n\tnumber = {10012},\n\turldate = {2020-08-23},\n\tjournal = {The Lancet},\n\tauthor = {Nichol, Alistair and French, Craig and Little, Lorraine and Haddad, Samir and Presneill, Jeffrey and Arabi, Yaseen and Bailey, Michael and Cooper, D James and Duranteau, Jacques and Huet, Olivier and Mak, Anne and McArthur, Colin and Pettilä, Ville and Skrifvars, Markus and Vallance, Shirley and Varma, Dinesh and Wills, Judy and Bellomo, Rinaldo},\n\tmonth = dec,\n\tyear = {2015},\n\tnote = {Number: 10012},\n\tpages = {2499--2506},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Effect of a Buffered Crystalloid Solution vs Saline on Acute Kidney Injury Among Patients in the Intensive Care Unit: The SPLIT Randomized Clinical Trial.\n \n \n \n \n\n\n \n Young, P.; Bailey, M.; Beasley, R.; Henderson, S.; Mackle, D.; McArthur, C.; McGuinness, S.; Mehrtens, J.; Myburgh, J.; Psirides, A.; Reddy, S.; and Bellomo, R.\n\n\n \n\n\n\n JAMA, 314(16): 1701. October 2015.\n Number: 16\n\n\n\n
\n\n\n\n \n \n \"EffectPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{young_effect_2015,\n\ttitle = {Effect of a {Buffered} {Crystalloid} {Solution} vs {Saline} on {Acute} {Kidney} {Injury} {Among} {Patients} in the {Intensive} {Care} {Unit}: {The} {SPLIT} {Randomized} {Clinical} {Trial}},\n\tvolume = {314},\n\tissn = {0098-7484},\n\tshorttitle = {Effect of a {Buffered} {Crystalloid} {Solution} vs {Saline} on {Acute} {Kidney} {Injury} {Among} {Patients} in the {Intensive} {Care} {Unit}},\n\turl = {http://jama.jamanetwork.com/article.aspx?doi=10.1001/jama.2015.12334},\n\tdoi = {10.1001/jama.2015.12334},\n\tlanguage = {en},\n\tnumber = {16},\n\turldate = {2020-08-23},\n\tjournal = {JAMA},\n\tauthor = {Young, Paul and Bailey, Michael and Beasley, Richard and Henderson, Seton and Mackle, Diane and McArthur, Colin and McGuinness, Shay and Mehrtens, Jan and Myburgh, John and Psirides, Alex and Reddy, Sumeet and Bellomo, Rinaldo},\n\tmonth = oct,\n\tyear = {2015},\n\tnote = {Number: 16},\n\tpages = {1701},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Acetaminophen for Fever in Critically Ill Patients with Suspected Infection.\n \n \n \n \n\n\n \n Young, P.; Saxena, M.; Bellomo, R.; Freebairn, R.; Hammond, N.; van Haren, F.; Holliday, M.; Henderson, S.; Mackle, D.; McArthur, C.; McGuinness, S.; Myburgh, J.; Weatherall, M.; Webb, S.; and Beasley, R.\n\n\n \n\n\n\n New England Journal of Medicine, 373(23): 2215–2224. December 2015.\n Number: 23\n\n\n\n
\n\n\n\n \n \n \"AcetaminophenPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{young_acetaminophen_2015,\n\ttitle = {Acetaminophen for {Fever} in {Critically} {Ill} {Patients} with {Suspected} {Infection}},\n\tvolume = {373},\n\tissn = {0028-4793, 1533-4406},\n\turl = {http://www.nejm.org/doi/10.1056/NEJMoa1508375},\n\tdoi = {10.1056/NEJMoa1508375},\n\tlanguage = {en},\n\tnumber = {23},\n\turldate = {2020-08-23},\n\tjournal = {New England Journal of Medicine},\n\tauthor = {Young, Paul and Saxena, Manoj and Bellomo, Rinaldo and Freebairn, Ross and Hammond, Naomi and van Haren, Frank and Holliday, Mark and Henderson, Seton and Mackle, Diane and McArthur, Colin and McGuinness, Shay and Myburgh, John and Weatherall, Mark and Webb, Steve and Beasley, Richard},\n\tmonth = dec,\n\tyear = {2015},\n\tnote = {Number: 23},\n\tpages = {2215--2224},\n}\n\n
\n
\n\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Using cardiac output monitoring to guide perioperative haemodynamic therapy.\n \n \n \n \n\n\n \n McGuinness, S.; and Parke, R.\n\n\n \n\n\n\n Current Opinion in Critical Care, 21(4). 2015.\n Number: 4\n\n\n\n
\n\n\n\n \n \n \"UsingPaper\n  \n \n\n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{mcguinness_using_2015,\n\ttitle = {Using cardiac output monitoring to guide perioperative haemodynamic therapy},\n\tvolume = {21},\n\tissn = {1070-5295},\n\turl = {https://journals.lww.com/co-criticalcare/Fulltext/2015/08000/Using_cardiac_output_monitoring_to_guide.15.aspx},\n\tabstract = {Purpose of review The aim of this study was to review recent advances and evidence for the use of cardiac output monitors to guide perioperative haemodynamic therapy. Recent findings There are multiple different cardiac output monitoring devices available for clinical use which are coupled with many different intervention protocols to manipulate perioperative haemodynamics. There is little evidence to demonstrate superiority of any one device. Previous small studies and meta-analyses have suggested that perioperative haemodynamic therapy guided by cardiac output monitoring improves outcomes after major surgery. Despite relatively low-quality evidence several national bodies have recommended ‘perioperative goal-directed therapy' (GDT) as a standard of care. Recent larger trials of GDT have mostly failed to prove a benefit of GDT and one explanation for this is the increased quality of usual care that may be occurring because of initiatives such as enhanced recovery after surgery and the WHO Safer Surgery programmes. Summary Perioperative GDT remains an exciting intervention to reduce significant morbidity following major surgery; however, it is not yet a proven standard of care. Further large pragmatic trials are required to demonstrate its effectiveness particularly in the era of enhanced recovery after surgery programmes.},\n\tnumber = {4},\n\tjournal = {Current Opinion in Critical Care},\n\tauthor = {McGuinness, Shay and Parke, Rachael},\n\tyear = {2015},\n\tnote = {Number: 4},\n\tkeywords = {cardiac output monitoring, goal directed therapy, haemodynamic optimization, perioperative care},\n}\n\n
\n
\n\n\n
\n Purpose of review The aim of this study was to review recent advances and evidence for the use of cardiac output monitors to guide perioperative haemodynamic therapy. Recent findings There are multiple different cardiac output monitoring devices available for clinical use which are coupled with many different intervention protocols to manipulate perioperative haemodynamics. There is little evidence to demonstrate superiority of any one device. Previous small studies and meta-analyses have suggested that perioperative haemodynamic therapy guided by cardiac output monitoring improves outcomes after major surgery. Despite relatively low-quality evidence several national bodies have recommended ‘perioperative goal-directed therapy' (GDT) as a standard of care. Recent larger trials of GDT have mostly failed to prove a benefit of GDT and one explanation for this is the increased quality of usual care that may be occurring because of initiatives such as enhanced recovery after surgery and the WHO Safer Surgery programmes. Summary Perioperative GDT remains an exciting intervention to reduce significant morbidity following major surgery; however, it is not yet a proven standard of care. Further large pragmatic trials are required to demonstrate its effectiveness particularly in the era of enhanced recovery after surgery programmes.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Stress ulcer prophylaxis in the intensive care unit: an international survey of 97 units in 11 countries.\n \n \n \n \n\n\n \n KRAG, M; PERNER, A; WETTERSLEV, J; WISE, M P; BORTHWICK, M; BENDEL, S; MCARTHUR, C; COOK, D; NIELSEN, N; PELOSI, P; KEUS, F; GUTTORMSEN, A B; MOLLER, A D; MØLLER, M H; and Collaborators, t. S.\n\n\n \n\n\n\n Acta Anaesthesiologica Scandinavica, 59(5): 576–585. May 2015.\n Number: 5 Publisher: John Wiley & Sons, Ltd (10.1111)\n\n\n\n
\n\n\n\n \n \n \"StressPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{krag_stress_2015,\n\ttitle = {Stress ulcer prophylaxis in the intensive care unit: an international survey of 97 units in 11 countries},\n\tvolume = {59},\n\tissn = {0001-5172},\n\turl = {https://doi.org/10.1111/aas.12508},\n\tdoi = {10.1111/aas.12508},\n\tabstract = {Background Stress ulcer prophylaxis (SUP) may decrease the incidence of gastrointestinal bleeding in patients in the intensive care unit (ICU), but the risk of infection may be increased. In this study, we aimed to describe SUP practices in adult ICUs. We hypothesised that patient selection for SUP varies both within and between countries. Methods Adult ICUs were invited to participate in the survey. We registered country, type of hospital, type and size of ICU, preferred SUP agent, presence of local guideline, reported indications for SUP, criteria for discontinuing SUP, and concerns about adverse effects. Fisher's exact test was used to assess differences between groups. Results Ninety-seven adult ICUs in 11 countries participated (eight European). All but one ICU used SUP, and 64\\% (62/97) reported having a guideline for the use of SUP. Proton pump inhibitors were the most common SUP agent, used in 66\\% of ICUs (64/97), and H2-receptor antagonists were used 31\\% (30/97) of the units. Twenty-three different indications for SUP were reported, the most frequent being mechanical ventilation. All patients were prescribed SUP in 26\\% (25/97) of the ICUs. Adequate enteral feeding was the most frequent reason for discontinuing SUP, but 19\\% (18/97) continued SUP upon ICU discharge. The majority expressed concern about nosocomial pneumonia and Clostridium difficile infection with the use of SUP. Conclusions In this international survey, most participating ICUs reported using SUP, primarily proton pump inhibitors, but many did not have a guideline; indications varied considerably and concern existed about infectious complications.},\n\tnumber = {5},\n\tjournal = {Acta Anaesthesiologica Scandinavica},\n\tauthor = {KRAG, M and PERNER, A and WETTERSLEV, J and WISE, M P and BORTHWICK, M and BENDEL, S and MCARTHUR, C and COOK, D and NIELSEN, N and PELOSI, P and KEUS, F and GUTTORMSEN, A B and MOLLER, A D and MØLLER, M H and Collaborators, the SUP-ICU},\n\tmonth = may,\n\tyear = {2015},\n\tnote = {Number: 5\nPublisher: John Wiley \\& Sons, Ltd (10.1111)},\n\tpages = {576--585},\n}\n\n
\n
\n\n\n
\n Background Stress ulcer prophylaxis (SUP) may decrease the incidence of gastrointestinal bleeding in patients in the intensive care unit (ICU), but the risk of infection may be increased. In this study, we aimed to describe SUP practices in adult ICUs. We hypothesised that patient selection for SUP varies both within and between countries. Methods Adult ICUs were invited to participate in the survey. We registered country, type of hospital, type and size of ICU, preferred SUP agent, presence of local guideline, reported indications for SUP, criteria for discontinuing SUP, and concerns about adverse effects. Fisher's exact test was used to assess differences between groups. Results Ninety-seven adult ICUs in 11 countries participated (eight European). All but one ICU used SUP, and 64% (62/97) reported having a guideline for the use of SUP. Proton pump inhibitors were the most common SUP agent, used in 66% of ICUs (64/97), and H2-receptor antagonists were used 31% (30/97) of the units. Twenty-three different indications for SUP were reported, the most frequent being mechanical ventilation. All patients were prescribed SUP in 26% (25/97) of the ICUs. Adequate enteral feeding was the most frequent reason for discontinuing SUP, but 19% (18/97) continued SUP upon ICU discharge. The majority expressed concern about nosocomial pneumonia and Clostridium difficile infection with the use of SUP. Conclusions In this international survey, most participating ICUs reported using SUP, primarily proton pump inhibitors, but many did not have a guideline; indications varied considerably and concern existed about infectious complications.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n Early mobilization and recovery in mechanically ventilated patients in the ICU: a bi-national, multi-centre, prospective cohort study.\n \n \n \n \n\n\n \n The TEAM Study Investigators\n\n\n \n\n\n\n Critical Care, 19(1): 81. 2015.\n Number: 1\n\n\n\n
\n\n\n\n \n \n \"EarlyPaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{the_team_study_investigators_early_2015,\n\ttitle = {Early mobilization and recovery in mechanically ventilated patients in the {ICU}: a bi-national, multi-centre, prospective cohort study},\n\tvolume = {19},\n\tissn = {1364-8535},\n\turl = {https://doi.org/10.1186/s13054-015-0765-4},\n\tdoi = {10.1186/s13054-015-0765-4},\n\tabstract = {The aim of this study was to investigate current mobilization practice, strength at ICU discharge and functional recovery at 6 months among mechanically ventilated ICU patients.},\n\tnumber = {1},\n\tjournal = {Critical Care},\n\tauthor = {{The TEAM Study Investigators}},\n\tyear = {2015},\n\tnote = {Number: 1},\n\tpages = {81},\n}\n\n
\n
\n\n\n
\n The aim of this study was to investigate current mobilization practice, strength at ICU discharge and functional recovery at 6 months among mechanically ventilated ICU patients.\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n A Randomised feasibility study to assess a novel strategy to rationalise fluid in patients after cardiac surgery.\n \n \n \n \n\n\n \n Parke, R L; McGuinness, S P; Gilder, E; McCarthy, L W; and Cowdrey, K. L\n\n\n \n\n\n\n British Journal of Anaesthesia, 115(1): 45–52. 2015.\n Number: 1\n\n\n\n
\n\n\n\n \n \n \"APaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n \n \n \n \n \n \n \n \n \n \n\n\n\n
\n 
@article{parke_randomised_2015,\n\ttitle = {A {Randomised} feasibility study to assess a novel strategy to rationalise fluid in patients after cardiac surgery},\n\tvolume = {115},\n\tissn = {0007-0912},\n\turl = {http://www.sciencedirect.com/science/article/pii/S0007091217312394},\n\tdoi = {https://doi.org/10.1093/bja/aev118},\n\tabstract = {Background After cardiac surgery, patients receive large amounts of fluid in the Intensive Care Unit (ICU). We plan to conduct a multi-centre randomised controlled trial, of a conservative fluid regime, in patients after cardiac surgery, and have reported results of a feasibility study that evaluated efficacy and safety of the proposed regime. Methods After ethical approval, a single-centre, prospectively randomised interventional study was undertaken. Participants were randomised to either usual care, or to a protocolised algorithm, utilising stroke volume variation, to guide fluid administration to patients who were deemed to have inadequate cardiac output and were likely to be volume responsive. The study protocol lasted from ICU admission to de-sedation or 24 h, whichever occurred first. Results We randomised 144 subjects over 9 months. Less bolus fluid and less total overall fluid volume was administered in the intervention group (median (IQR) 1620 ml (500–3410) and 2525 ml (1440–5250; P{\\textbackslash}textless0.001), compared with the usual care group (2050 ml (910–4280) and 2980 ml (2070–6580; P=0.001), from ICU admission to extubation. There was no significant difference in incidence of acute kidney injury or the average amount of fluid administered to the usual care group at the beginning compared with the end of the study. Conclusion It is both possible and safe to achieve a significant reduction in the amount of fluid administered to patients, allocated to a conservative fluid protocol. These results suggest that a planned multi-centre study is both justified and feasible. Clinical trial registration Australia New Zealand Clinical Trials Registry www.anzctr.org.au (ACTRN12612000754842).},\n\tnumber = {1},\n\tjournal = {British Journal of Anaesthesia},\n\tauthor = {Parke, R L and McGuinness, S P and Gilder, E and McCarthy, L W and Cowdrey, K.-A. L},\n\tyear = {2015},\n\tnote = {Number: 1},\n\tkeywords = {acute kidney injury, cardiac output, cardiac surgery, haemodynamics, intensive care units},\n\tpages = {45--52},\n}\n\n
\n
\n\n\n
\n Background After cardiac surgery, patients receive large amounts of fluid in the Intensive Care Unit (ICU). We plan to conduct a multi-centre randomised controlled trial, of a conservative fluid regime, in patients after cardiac surgery, and have reported results of a feasibility study that evaluated efficacy and safety of the proposed regime. Methods After ethical approval, a single-centre, prospectively randomised interventional study was undertaken. Participants were randomised to either usual care, or to a protocolised algorithm, utilising stroke volume variation, to guide fluid administration to patients who were deemed to have inadequate cardiac output and were likely to be volume responsive. The study protocol lasted from ICU admission to de-sedation or 24 h, whichever occurred first. Results We randomised 144 subjects over 9 months. Less bolus fluid and less total overall fluid volume was administered in the intervention group (median (IQR) 1620 ml (500–3410) and 2525 ml (1440–5250; P\\textless0.001), compared with the usual care group (2050 ml (910–4280) and 2980 ml (2070–6580; P=0.001), from ICU admission to extubation. There was no significant difference in incidence of acute kidney injury or the average amount of fluid administered to the usual care group at the beginning compared with the end of the study. Conclusion It is both possible and safe to achieve a significant reduction in the amount of fluid administered to patients, allocated to a conservative fluid protocol. These results suggest that a planned multi-centre study is both justified and feasible. Clinical trial registration Australia New Zealand Clinical Trials Registry www.anzctr.org.au (ACTRN12612000754842).\n
\n\n\n
\n\n\n
\n \n\n \n \n \n \n \n \n A Multicenter Randomized Trial of Continuous versus Intermittent β-Lactam Infusion in Severe Sepsis.\n \n \n \n \n\n\n \n Dulhunty, J. M; Roberts, J. A; Davis, J. S; Webb, S. A R; Bellomo, R.; Gomersall, C.; Shirwadkar, C.; Eastwood, G. M; Myburgh, J.; Paterson, D. L; Starr, T.; Paul, S. K; and Lipman, J.\n\n\n \n\n\n\n American Journal of Respiratory and Critical Care Medicine, 192(11): 1298–1305. July 2015.\n Number: 11 Publisher: American Thoracic Society - AJRCCM\n\n\n\n
\n\n\n\n \n \n \"APaper\n  \n \n\n \n \n doi\n  \n \n\n \n link\n  \n \n\n bibtex\n \n\n \n  \n \n abstract \n \n\n \n\n \n \n \n \n \n \n \n\n  \n \n \n\n\n\n
\n 
@article{dulhunty_multicenter_2015,\n\ttitle = {A {Multicenter} {Randomized} {Trial} of {Continuous} versus {Intermittent} β-{Lactam} {Infusion} in {Severe} {Sepsis}},\n\tvolume = {192},\n\tissn = {1073-449X},\n\turl = {https://doi.org/10.1164/rccm.201505-0857OC},\n\tdoi = {10.1164/rccm.201505-0857OC},\n\tabstract = {Rationale: Continuous infusion of ?-lactam antibiotics may improve outcomes because of time-dependent antibacterial activity compared with intermittent dosing.Objectives: To evaluate the efficacy of continuous versus intermittent infusion in patients with severe sepsis.Methods: We conducted a randomized controlled trial in 25 intensive care units (ICUs). Participants commenced on piperacillin?tazobactam, ticarcillin?clavulanate, or meropenem were randomized to receive the prescribed antibiotic via continuous or 30-minute intermittent infusion for the remainder of the treatment course or until ICU discharge. The primary outcome was the number of alive ICU-free days at Day 28. Secondary outcomes were 90-day survival, clinical cure 14 days post antibiotic cessation, alive organ failure?free days at Day 14, and duration of bacteremia.Measurements and Main Results: We enrolled 432 eligible participants with a median age of 64 years and an Acute Physiology and Chronic Health Evaluation II score of 20. There was no difference in ICU-free days: 18 days (interquartile range, 2?24) and 20 days (interquartile range, 3?24) in the continuous and intermittent groups (P?=?0.38). There was no difference in 90-day survival: 74.3\\% (156 of 210) and 72.5\\% (158 of 218); hazard ratio, 0.91 (95\\% confidence interval, 0.63?1.31; P?=?0.61). Clinical cure was 52.4\\% (111 of 212) and 49.5\\% (109 of 220); odds ratio, 1.12 (95\\% confidence interval, 0.77?1.63; P?=?0.56). There was no difference in organ failure?free days (6 d; P?=?0.27) and duration of bacteremia (0 d; P?=?0.24).Conclusions: In critically ill patients with severe sepsis, there was no difference in outcomes between ?-lactam antibiotic administration by continuous and intermittent infusion.Australian New Zealand Clinical Trials Registry number (ACT RN12612000138886).},\n\tnumber = {11},\n\tjournal = {American Journal of Respiratory and Critical Care Medicine},\n\tauthor = {Dulhunty, Joel M and Roberts, Jason A and Davis, Joshua S and Webb, Steven A R and Bellomo, Rinaldo and Gomersall, Charles and Shirwadkar, Charudatt and Eastwood, Glenn M and Myburgh, John and Paterson, David L and Starr, Therese and Paul, Sanjoy K and Lipman, Jeffrey},\n\tmonth = jul,\n\tyear = {2015},\n\tnote = {Number: 11\nPublisher: American Thoracic Society - AJRCCM},\n\tpages = {1298--1305},\n}\n\n
\n
\n\n\n
\n Rationale: Continuous infusion of ?-lactam antibiotics may improve outcomes because of time-dependent antibacterial activity compared with intermittent dosing.Objectives: To evaluate the efficacy of continuous versus intermittent infusion in patients with severe sepsis.Methods: We conducted a randomized controlled trial in 25 intensive care units (ICUs). Participants commenced on piperacillin?tazobactam, ticarcillin?clavulanate, or meropenem were randomized to receive the prescribed antibiotic via continuous or 30-minute intermittent infusion for the remainder of the treatment course or until ICU discharge. The primary outcome was the number of alive ICU-free days at Day 28. Secondary outcomes were 90-day survival, clinical cure 14 days post antibiotic cessation, alive organ failure?free days at Day 14, and duration of bacteremia.Measurements and Main Results: We enrolled 432 eligible participants with a median age of 64 years and an Acute Physiology and Chronic Health Evaluation II score of 20. There was no difference in ICU-free days: 18 days (interquartile range, 2?24) and 20 days (interquartile range, 3?24) in the continuous and intermittent groups (P?=?0.38). There was no difference in 90-day survival: 74.3% (156 of 210) and 72.5% (158 of 218); hazard ratio, 0.91 (95% confidence interval, 0.63?1.31; P?=?0.61). Clinical cure was 52.4% (111 of 212) and 49.5% (109 of 220); odds ratio, 1.12 (95% confidence interval, 0.77?1.63; P?=?0.56). There was no difference in organ failure?free days (6 d; P?=?0.27) and duration of bacteremia (0 d; P?=?0.24).Conclusions: In critically ill patients with severe sepsis, there was no difference in outcomes between ?-lactam antibiotic administration by continuous and intermittent infusion.Australian New Zealand Clinical Trials Registry number (ACT RN12612000138886).\n
\n\n\n
\n\n\n\n\n\n
\n
\n\n\n\n\n
\n\n\n \n\n \n \n \n \n\n
\n"}; document.write(bibbase_data.data);